Practical,O
Considerations,O
for,O
Solid,O
Organ,O
Transplantation,O
During,O
the,O
COVID,O
‐,O
19,NUMBER
Global,O
Outbreak,O
:,O
The,O
Experience,O
from,O
Singapore,COUNTRY
Shimin,PERSON
Jasmine,PERSON
Chung,PERSON
.,O
MBBS,O
.,O
BSc,O
.,O
MRCP,O
(,O
UK,COUNTRY
),O
.1.2,O
Ek,PERSON
Khoon,PERSON
Tan,PERSON
.,O
MBBS,O
.,O
MMed,O
.,O
MPH,O
.,O
FRCSEd,O
.2.3,O
Terence,PERSON
Kee,PERSON
.,O
MBBS,O
.,O
MRCP,O
(,O
UK,COUNTRY
),O
.,O
FAMS,O
.,O
FRCP,ORGANIZATION
.,O
FASN,O
.2.4,NUMBER
Thinesh,PERSON
Lee,PERSON
Krishnamoorthy,PERSON
.,O
MBChB,O
.,O
BSc,O
.,O
MRCP,O
(,O
UK,COUNTRY
),O
.2.5,O
Ghee,PERSON
Chee,PERSON
Phua,PERSON
.,O
MBBS,O
.,O
MMed,O
.,O
MRCP,O
(,O
UK,COUNTRY
),O
.,O
FAMS,O
.,O
FCCP,O
.,O
EDIC,ORGANIZATION
.2.6,NUMBER
Duu,PERSON
Wen,PERSON
Sewa,PERSON
.,O
MBBS,O
.,O
MRCP,O
(,O
UK,COUNTRY
),O
.2.6,O
Boon,O
‐,O
Hean,PERSON
Ong,PERSON
.,O
MBBS,O
.,O
MRCSEd,O
.,O
FRCSEd,O
(,O
CTh,MISC
),O
.,O
FAMS,O
.2.7,O
Teing,PERSON
Ee,PERSON
Tan,PERSON
.,O
MBBS,O
.,O
FRCSEd,O
.2.7,O
Cumaraswamy,PERSON
Sivathasan,PERSON
.,O
MBBS,ORGANIZATION
.,O
FRCS,O
(,O
Eng,O
/,O
Edin,PERSON
),O
.,O
FAMS,O
.2.7,O
Huei,PERSON
Li,PERSON
Valerie,PERSON
Gan,PERSON
.,O
MBBS,O
.,O
MRCS,ORGANIZATION
.,O
MMed,O
.,O
FAMS,O
.2.8,O
Brian,PERSON
Kim,PERSON
Poh,PERSON
Goh,PERSON
.,O
MBBS,O
.,O
MMed,O
.,O
MSc,O
.,O
FRCSEd,O
.,O
FAMS,O
.2.3,O
Prema,PERSON
Raj,PERSON
Jeyaraj,PERSON
.,O
MBBS,O
.,O
Mmed,O
.,O
FRCS,O
(,O
Glasg,O
),O
.,O
FRCS,O
(,O
Ed,MISC
),O
.,O
FAMS,O
.2.3,O
and,O
Ban,PERSON
Hock,PERSON
Tan,PERSON
.,O
MBBS,O
.,O
FRCP,O
(,O
UK,COUNTRY
),O
1.2,NUMBER
Abstract,O
.,O
The,O
current,DATE
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
pandem,O
‐,O
ic,O
has,O
not,O
only,O
caused,O
global,O
social,O
disruptions,O
but,O
has,O
also,O
put,O
tremendous,O
strain,O
on,O
healthcare,O
systems,O
worldwide,O
.,O
With,O
all,O
at,O
‐,O
tention,O
and,O
significant,O
effort,O
diverted,O
to,O
containing,O
and,O
manag,O
‐,O
ing,O
the,O
COVID,O
‐,O
19,NUMBER
outbreak,O
(,O
and,O
understandably,O
so,O
),O
.,O
essential,O
med,O
‐,O
ical,O
services,O
such,O
as,O
transplant,O
services,O
are,O
likely,O
to,O
be,O
af,O
‐,O
fected,O
.,O
Closure,O
of,O
transplant,O
programs,O
in,O
an,O
outbreak,O
caused,O
by,O
a,O
highly,O
transmissible,O
novel,O
pathogen,O
die,O
before,O
the,O
program,O
re,O
‐,O
opens,O
.,O
By,O
adopting,O
a,O
tiered,O
approach,O
based,O
on,O
outbreak,O
disease,CAUSE_OF_DEATH
alert,O
levels,O
.,O
and,O
having,O
hospital,O
guidelines,O
based,O
on,O
the,O
best,O
available,O
evidence,O
.,O
life,O
‐,O
saving,O
transplants,O
can,O
still,O
be,O
safely,O
performed,O
.,O
We,O
performed,O
a,O
lung,O
transplant,O
and,O
a,O
liver,O
transplant,O
successfully,O
during,O
the,O
COVID,O
‐,O
19,NUMBER
era,O
.,O
We,O
present,DATE
our,O
guidelines,O
and,O
experience,O
on,O
managing,O
the,O
transplant,O
service,O
as,O
well,O
as,O
the,O
selection,O
and,O
management,O
of,O
donors,O
and,O
recipients,O
.,O
We,O
also,O
dis,O
‐,O
cuss,O
clinical,O
dilemmas,O
in,O
the,O
management,O
COVID,O
‐,O
19,NUMBER
in,O
the,O
post,O
‐,O
transplant,O
recipient,O
.,O
ecause,O
of,O
the,O
emergence,O
of,O
a,O
novel,O
coron,O
‐,O
avirus,O
(,O
now,DATE
called,O
Severe,O
Acute,O
Respiratory,O
Distress,O
Syndrome,O
[,O
SARS,O
],O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
causing,O
the,O
disease,CAUSE_OF_DEATH
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
[,O
COVID,O
‐,O
19,NUMBER
],O
),O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
in,O
December,DATE
2019,DATE
.,O
there,O
has,O
been,O
an,O
exponential,O
increase,O
in,O
the,O
global,O
number,O
of,O
confirmed,O
cases,O
.,O
There,O
are,O
now,DATE
>,O
2,NUMBER
million,NUMBER
cases,O
in,O
>,O
200,NUMBER
countries,O
.,O
The,O
ongoing,O
COVID,O
‐,O
19,NUMBER
outbreak,O
has,O
outstripped,O
the,O
2003,DATE
SARS,O
in,O
scale,O
and,O
worldwide,O
extent,O
.,O
leading,O
the,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
to,O
offi,O
‐,O
cially,O
declare,O
it,O
a,O
pandemic,O
on,O
March,DATE
11,DATE
.,O
2020.1,NUMBER
The,O
evolution,O
of,O
COVID,O
‐,O
19,NUMBER
and,O
the,O
containment,O
efforts,O
to,O
combat,O
it,O
are,O
reminiscent,O
of,O
SARS,O
.,O
The,O
potential,O
for,O
healthcare,O
systems,O
to,O
be,O
crippled,O
by,O
this,O
pandemic,O
is,O
real,O
and,O
looming,O
.,O
Essential,O
medical,O
services,O
may,O
be,O
affected,O
.,O
as,O
hospitals,O
commandeer,O
resources,O
to,O
care,O
for,O
COVID,O
‐,O
19,NUMBER
patients,O
and,O
suspects,O
.2,NUMBER
During,O
SARS,O
.,O
cities,O
experiencing,O
community,O
transmission,O
.,O
such,O
as,O
Singapore,COUNTRY
and,O
Toronto,CITY
.,O
closed,O
their,O
transplant,O
programs,O
temporarily,O
.3.4,NUMBER
Although,O
SARS,O
came,O
un,O
‐,O
der,O
control,O
after,O
a,DURATION
few,DURATION
months,DURATION
.,O
allowing,O
transplantation,O
to,O
re,O
‐,O
sume,O
.,O
the,O
current,DATE
COVID,O
‐,O
19,NUMBER
outbreak,O
may,O
be,O
long,O
‐,O
drawn,O
.,O
Organ,O
transplantation,O
is,O
an,O
essential,O
medical,O
service,O
and,O
can,O
not,O
be,O
put,O
on,O
hold,O
indefinitely,O
or,O
for,O
a,O
prolonged,O
period,O
of,O
time,O
without,O
compromising,O
patients,O
on,O
the,O
waiting,O
list,O
.,O
Thus,O
.,O
Department,O
of,O
Infectious,O
Diseases,CAUSE_OF_DEATH
.,O
Singapore,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Singapore,COUNTRY
.,O
SingHealth,O
Duke,TITLE
‐,O
NUS,O
Transplant,O
Centre,O
.,O
Singapore,COUNTRY
.,O
Department,O
of,O
Hepatopancreatobiliary,O
and,O
Transplant,O
Surgery,CAUSE_OF_DEATH
.,O
Singapore,COUNTRY
General,TITLE
Hospital,O
.,O
Singapore,COUNTRY
.,O
Department,O
of,O
Gasteroentrology,LOCATION
and,O
Hepatol,O
‐,O
ogy,O
.,O
Singapore,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Department,O
of,O
Respiratory,O
and,O
Critical,O
Care,O
Medicine,O
.,O
Singapore,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Singapore,COUNTRY
.,O
Department,O
of,O
Cardiothoracic,O
Surgery,CAUSE_OF_DEATH
.,O
National,O
Heart,O
Centre,O
.,O
Sin,O
‐,O
gapore,O
.,O
Department,ORGANIZATION
of,ORGANIZATION
Renal,ORGANIZATION
Medicine,ORGANIZATION
Singapore,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Singapore,COUNTRY
.,O
Department,ORGANIZATION
of,ORGANIZATION
Urology,ORGANIZATION
.,O
Singapore,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Singapore,COUNTRY
.,O
S.J.C.,O
.,O
E.K.T.,O
.,O
T.K.,PERSON
.,O
P.R.J.,O
.,O
and,O
B.H.T.,O
participated,O
in,O
the,O
writing,O
of,O
the,O
paper,O
.,O
S.J.C.,O
.,O
E.K.T.,O
.,O
T.L.K.,O
.,O
G.C.P.,O
.,O
D.W.S.,O
.,O
B.,O
‐,O
H.O.,O
.,O
T.E.T.,O
.,O
C.S.,LOCATION
.,O
T.K.,PERSON
.,O
H.L.V.G.,O
.,O
B.K.P.G.,O
.,O
P.R.J.,O
.,O
and,O
B.H.T.,O
drafted,O
the,O
institutional,O
guidelines,O
.,O
Correspondence,O
:,O
Shimin,PERSON
Jasmine,PERSON
Chung,PERSON
.,O
MBBS,O
.,O
BSc,O
.,O
MRCP,O
(,O
UK,COUNTRY
),O
.,O
Department,O
of,O
Infec,O
‐,O
tious,O
Diseases,CAUSE_OF_DEATH
.,O
SGH,O
.,O
The,O
Academia,ORGANIZATION
Level,ORGANIZATION
3,NUMBER
.,O
20,NUMBER
College,O
Rd,O
.,O
Singa,O
‐,O
pore,O
Transplantation,O
DIRECT,O
(,O
CCBY,O
‐,O
NC,STATE_OR_PROVINCE
‐,O
ND,STATE_OR_PROVINCE
),O
.,O
where,O
it,O
is,O
permissible,O
to,O
download,O
and,O
share,O
the,O
work,O
provided,O
Transplantation,O
DIRECT,O
this,O
outbreak,O
.,O
we,O
the,O
transplant,O
community,O
have,O
to,O
evaluate,O
how,O
best,O
to,O
continue,O
providing,O
transplant,O
care,O
during,O
these,O
trying,O
times,O
.,O
Here,O
.,O
in,O
Singapore,COUNTRY
.,O
evidence,O
of,O
local,O
transmission,O
oc,O
‐,O
curred,O
shortly,O
after,O
the,O
first,ORDINAL
imported,O
cases,O
were,O
diagnosed,O
.5,NUMBER
Having,O
survived,O
the,O
tragedy,O
of,O
SARS,O
.,O
our,O
hospital,O
had,O
swung,O
into,O
crisis,O
mode,O
early,O
.,O
freeing,O
the,O
negative,O
‐,O
pressure,O
isolation,O
ward,O
of,O
its,O
usual,O
patients,O
(,O
eg,O
.,O
those,O
with,O
tuberculosis,CAUSE_OF_DEATH
.,O
carbapenemre,O
‐,O
sistant,O
Enterobacteriaceae,O
),O
and,O
reducing,O
the,O
number,O
of,O
elective,O
surgeries,O
to,O
create,O
bed,O
capacity,O
.,O
Strict,O
infection,CAUSE_OF_DEATH
prevention,O
protocols,O
were,O
implemented,O
.,O
and,O
compliance,O
audits,O
were,O
started,O
.,O
The,O
heightened,O
level,O
of,O
operations,O
and,O
the,O
desire,O
to,O
maintain,O
transplant,O
as,O
an,O
essential,O
service,O
prompted,O
us,O
to,O
develop,O
inter,O
‐,O
nal,O
guidelines,O
on,O
the,O
selection,O
and,O
management,O
of,O
donors,O
and,O
re,O
‐,O
cipients,O
for,O
transplantation,O
in,O
the,O
setting,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Shortly,O
thereafter,O
.,O
a,O
brain,O
‐,O
dead,O
donor,O
was,O
identified,O
.,O
We,O
implemented,O
these,O
guidelines,O
and,O
proceeded,O
to,O
perform,O
a,O
deceased,O
‐,O
donor,O
lung,O
and,O
a,O
liver,O
transplant,O
.,O
The,O
aim,O
of,O
to,O
continue,O
provision,O
of,O
organ,O
transplantation,O
services,O
during,O
this,O
pandemic,O
.,O
Specifically,O
.,O
we,O
want,O
to,O
highlight,O
the,O
need,O
for,O
a,O
tiered,O
approach,O
as,O
the,O
pandemic,O
evolves,O
.,O
EVOLVING,O
EPIDEMIOLOGY,O
OF,O
COVID,O
‐,O
19,NUMBER
AND,O
ITS,O
IMPACT,O
ON,O
DE,STATE_OR_PROVINCE
‐,O
CISION,O
FOR,O
TRANSPLANT,O
The,O
first,ORDINAL
reported,O
cluster,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infected,O
individuals,O
in,O
December,DATE
2019,DATE
was,O
reportedly,O
linked,O
to,O
a,O
large,O
seafood,O
and,O
live,O
animal,O
market,O
in,O
Wuhan,CITY
.,LOCATION
Hubei,STATE_OR_PROVINCE
Province,LOCATION
.,O
China,COUNTRY
.,O
suggesting,O
a,O
zoonotic,O
origin,O
for,O
this,O
novel,O
pathogen,O
.,O
De,O
‐,O
spite,O
early,O
closure,O
of,O
the,O
market,O
with,O
attempts,O
made,O
to,O
isolate,O
suspects,O
and,O
closely,O
monitor,O
contacts,O
.,O
by,O
mid,O
‐,O
January,DATE
2020,DATE
.,O
COVID,O
‐,O
19,NUMBER
had,O
spread,O
widely,O
across,O
China,COUNTRY
and,O
exported,O
cases,O
were,O
reported,O
mainly,O
in,O
the,O
Asia,CITY
Pacific,LOCATION
region,O
.,O
suggesting,O
that,O
hu,O
‐,O
man,O
‐,O
to,O
‐,O
human,O
transmission,O
(,O
through,O
droplets,O
or,O
direct,O
contact,O
),O
had,O
become,O
more,O
common,O
.6,NUMBER
‐,O
9,NUMBER
International,O
travel,O
further,O
facili,O
‐,O
tated,O
the,O
global,O
spread,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
As,O
we,O
now,DATE
know,O
.,O
SARSCoV,O
‐,O
2,NUMBER
is,O
highly,O
transmissible,O
with,O
a,O
reported,O
reproduction,O
number,O
(,O
R0,O
),O
be,O
‐,O
tween,O
1.4,NUMBER
and,O
5.5.10,DATE
Asymptomatic,O
and,O
presymptomatic,O
transmission,O
before,O
isolation,O
.,O
quarantine,O
.,O
social,O
distancing,O
.,O
and,O
community,O
containment,O
efforts,O
likely,O
contributed,O
to,O
the,O
surge,O
of,O
cases,O
globally,O
.6.8.11,NUMBER
‐,O
13,NUMBER
Based,O
on,O
current,DATE
understanding,O
of,O
influenza,CAUSE_OF_DEATH
pandemics,O
.14,O
we,O
had,O
anticipated,O
that,O
the,O
COVID,O
‐,O
19,NUMBER
outbreak,O
would,O
reach,O
Singapore,COUNTRY
(,O
and,O
other,O
parts,O
of,O
the,O
world,O
),O
.,O
Once,DATE
human,O
‐,O
tohu,O
‐,O
man,O
transmission,O
was,O
established,O
.,O
infections,CAUSE_OF_DEATH
would,O
be,O
imported,O
from,O
affected,O
areas,O
resulting,O
in,O
the,O
emergence,O
of,O
local,O
clusters,O
.,O
and,O
subsequently,O
widespread,O
community,O
transmission,O
with,O
unlinked,O
cases,O
.,O
particularly,O
among,O
densely,O
populated,O
cities,O
like,O
Singa,O
‐,O
pore,O
.5.6.13,NUMBER
As,O
the,O
situation,O
was,O
rapidly,O
evolving,O
.,O
we,O
envisioned,O
a,O
stratified,O
decision,O
‐,O
making,O
process,O
to,O
allow,O
our,O
transplant,O
ser,O
‐,O
vice,O
to,O
respond,O
to,O
different,O
phases,O
of,O
the,O
pandemic,O
.,O
We,O
developed,O
exercised,O
.,O
restricting,O
transplantation,O
to,O
those,O
who,O
require,O
it,O
urgently,O
and,O
can,O
not,O
wait,O
.,O
Living,O
donor,O
transplantation,O
activity,O
.,O
compared,O
to,O
deceased,O
organ,O
donation,O
.,O
will,O
be,O
reduced,O
due,O
to,O
the,O
need,O
to,O
protect,O
the,O
interests,O
of,O
the,O
living,O
donor,O
.,O
In,O
general,TITLE
.,O
urgent,O
transplants,O
refer,O
to,O
patients,O
with,O
the,O
following,O
condi,O
‐,O
tions,O
:,O
(,O
1,NUMBER
),O
liver,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
with,O
a,O
high,O
28,NUMBER
‐,O
d,O
mortality,O
;,O
(,O
2,NUMBER
),O
heart,O
failure,O
patients,O
who,O
are,O
on,O
extracorporeal,O
circulatory,O
support,O
.,O
or,O
mechanical,O
circulatory,O
support,O
(,O
MCS,O
),O
with,O
evidence,O
of,O
device,O
‐,O
related,O
complications,CAUSE_OF_DEATH
or,O
those,O
who,O
require,O
continuous,O
high,O
‐,O
dose,O
inotropic,O
support,O
;,O
or,O
(,O
3,NUMBER
),O
patients,O
with,O
end,O
‐,O
stage,O
lung,O
disease,CAUSE_OF_DEATH
who,O
can,O
not,O
sustain,O
long,O
on,O
the,O
waitlist,O
.,O
The,O
urgency,O
to,O
perform,O
liver,O
transplantation,O
for,O
patients,O
with,O
hepatocellular,O
carcinomas,O
depends,O
on,O
their,O
transplant,O
oncologic,O
profile,O
and,O
whether,O
bridg,O
‐,O
ing,O
therapy,O
is,O
an,O
option,O
.,O
MCS,O
and,O
(,O
2,NUMBER
),O
those,O
with,O
end,O
‐,O
stage,O
renal,O
failure,O
awaiting,O
kidney,O
transplantation,O
but,O
have,O
no,O
urgent,O
issues,O
with,O
dialysis,O
access,O
.15,NUMBER
Apart,O
from,O
urgency,O
of,O
transplant,O
.,O
an,O
in,O
‐,O
dividualized,O
risk,O
assessment,O
of,O
the,O
recipient,O
based,O
on,O
the,O
com,O
‐,O
plexity,O
of,O
the,O
transplant,O
procedure,O
.,O
extent,O
of,O
medical,O
comorbidi,O
‐,O
ties,O
.,O
and,O
immunologic,O
risk,O
is,O
also,O
required,O
.,O
A,O
medically,O
and,O
sur,O
‐,O
gically,O
complex,O
candidate,TITLE
may,O
require,O
extraordinary,O
resources,O
such,O
as,O
an,O
extended,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
stay,O
.,O
large,O
amounts,O
of,O
blood,O
products,O
.,O
or,O
subspecialty,O
support,O
;,O
these,O
may,O
not,O
be,O
promptly,O
available,O
when,O
hospital,O
resources,O
and,O
manpower,O
are,O
di,O
‐,O
verted,O
away,O
.,O
The,O
infective,O
nature,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
and,O
the,O
implica,O
‐,O
tions,O
on,O
immunosuppression,O
also,O
imply,O
that,O
performing,O
transplants,O
with,O
a,O
higher,O
immunological,O
risk,O
of,O
rejection,O
such,O
as,O
ABO,O
‐,O
incom,O
‐,O
patible,O
transplant,O
or,O
transplants,O
for,O
highly,O
sensitized,O
recipi,O
‐,O
ents,O
may,O
come,O
at,O
an,O
increased,O
risk,O
.,O
With,O
that,O
in,O
mind,O
.,O
we,O
devel,O
‐,O
oped,O
a,O
decision,O
‐,O
making,O
grid,O
to,O
that,O
organ,O
.,O
against,O
the,O
principle,O
of,O
ideal,O
patient,O
selection,O
for,O
a,O
procedure,O
.,O
by,O
recognizing,O
the,O
fact,O
that,O
a,O
successful,O
patient,O
outcome,O
is,O
intimately,O
dependent,O
on,O
the,O
resources,O
that,O
are,O
COVID,O
‐,O
19,NUMBER
SITUATION,O
IN,O
SINGAPORE,COUNTRY
AND,O
POLICY,O
STATEMENTS,O
FROM,O
THE,O
MINISTRY,O
OF,O
HEALTH,O
Singapores,O
first,ORDINAL
patient,O
with,O
COVID,O
‐,O
19,NUMBER
was,O
an,O
imported,O
case,O
that,O
was,O
diagnosed,O
at,O
our,O
hos,O
‐,O
pital,O
.,O
Local,O
transmission,O
occurred,O
within,O
2,DURATION
wk,DURATION
and,O
several,O
local,O
chains,O
of,O
transmission,O
were,O
later,O
identified,O
.5,NUMBER
Through,O
media,O
re,O
‐,O
ports,O
.,O
this,O
sequence,O
of,O
events,O
has,O
been,O
played,O
out,O
many,O
times,O
in,O
different,O
countries,O
.,O
In,O
certain,O
countries,O
.,O
even,O
the,O
earliest,O
cases,O
have,O
not,O
had,O
travel,O
links,O
.2.6,NUMBER
The,O
ability,O
to,O
identify,O
the,O
local,O
chains,O
of,O
transmission,O
is,O
attributed,O
to,O
the,O
Singapore,COUNTRY
gov,O
‐,O
ernment,O
establishing,O
a,O
Ministerial,O
taskforce,O
that,O
.,O
under,O
the,O
aus,O
‐,O
pices,O
of,O
the,O
Infectious,MISC
Diseases,CAUSE_OF_DEATH
Act,MISC
.,O
performed,O
extensive,O
contact,O
tracing,O
of,O
infected,O
and,O
exposed,O
individuals,O
.,O
On,O
February,DATE
19,DATE
.,O
2020,DATE
.,O
the,O
local,O
Ministry,ORGANIZATION
of,ORGANIZATION
Health,ORGANIZATION
(,O
MOH,O
),O
issued,O
a,O
statement,O
al,O
‐,O
lowing,O
living,O
donor,O
transplants,O
to,O
proceed,O
.,O
while,O
temporarily,O
banning,O
all,O
nonurgent,O
deceased,O
donor,O
transplants,O
.15,NUMBER
As,O
the,O
epi,O
‐,O
demiologic,O
curve,O
of,O
incident,O
COVID19,O
cases,O
in,O
Singapore,COUNTRY
flattened,O
toward,O
the,DATE
end,DATE
of,DATE
February,DATE
2020,DATE
.,O
MOH,O
allowed,O
nonurgent,O
deceased,O
donor,O
transplants,O
as,O
well,O
.,O
provided,O
the,O
earlier,O
criteria,O
were,O
met,O
(,O
communication,O
with,O
MOH,O
.,O
Singapore,COUNTRY
on,O
March,DATE
3,DATE
.,DATE
2020,DATE
),O
.,O
By,O
then,O
.,O
our,O
workgroup,O
had,O
developed,O
guidelines,O
on,O
how,O
we,O
would,O
proceed,O
with,O
transplantation,O
safely,O
.,O
The,O
thought,O
processes,O
and,O
measures,O
adopted,O
are,O
described,O
in,O
the,O
subsequent,O
sections,O
.,O
Chung,O
et,O
al,O
Impact,O
of,O
disease,CAUSE_OF_DEATH
outbreak,O
alerts,O
on,O
transplantation,O
programs,O
DORSCON,O
alert45,O
Extent,O
of,O
COVID,O
‐,O
19,NUMBER
Transmission,O
predominantly,O
within,O
Hubei,STATE_OR_PROVINCE
Province,LOCATION
.,O
China,COUNTRY
Rare,O
cases,O
exported,O
outside,O
of,O
China,COUNTRY
Increased,O
transmission,O
to,O
multiple,O
provinces,O
and,O
municipalities,O
in,O
China,COUNTRY
Increasing,O
number,O
of,O
exported,O
cases,O
outside,O
of,O
China,COUNTRY
Im,O
‐,O
ported,O
case,O
to,O
Singapore,COUNTRY
;,O
no,O
local,O
transmission,O
.,O
No,O
case,O
fatality,O
Widespread,O
transmission,O
within,O
China,COUNTRY
Significant,O
number,O
of,O
ex,O
‐,O
ported,O
cases,O
outside,O
of,O
China,COUNTRY
.,O
in,O
a,O
few,O
WHO,O
regions,O
.,O
Reports,O
of,O
community,O
transmission,O
outside,O
of,O
China,COUNTRY
Local,O
transmission,O
WITHIN,O
Singapore,COUNTRY
.,O
Severe,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
reported,O
Red,O
(,O
very,O
high,O
),O
Widespread,O
global,O
transmission,O
Ongoing,O
community,O
transmission,O
in,O
Risk,O
of,O
increased,O
number,O
of,O
severe,O
Deceased,MISC
donor,O
transplant,O
pro,O
‐,O
gram,O
Living,O
donor,O
transplant,O
program,O
Nil,O
restrictions,O
Nil,O
re,O
‐,O
strictions,O
Organ,MISC
donors,O
with,O
positive,O
travel,O
history,O
to,O
affected,O
To,O
defer,O
transplant,O
for,O
1428,DATE
d,O
if,O
organ,O
donors,O
region,O
may,O
be,O
re,O
‐,O
jected,O
upon,O
advice,O
from,O
TxID,O
had,O
positive,O
contact,O
history,O
or,O
travel,O
history,O
to,O
affected,O
areas,O
Although,O
restrictions,O
not,O
im,O
‐,O
posed,O
.,O
to,O
proceed,O
with,O
Nil,O
restrictions,O
.,O
Thorough,O
screening,O
of,O
donor,O
transplant,O
with,O
caution,O
and,O
recipients,O
through,O
clinical,O
history,O
taking,O
Active,O
screeningc,O
and,O
exclusion,O
of,O
donors,O
and,O
re,O
‐,O
cipients,O
at,O
risk,O
of,O
COVID,O
‐,O
19,NUMBER
(,O
based,O
on,O
history,O
Active,O
screeningc,O
of,O
donors,O
and,O
recipients,O
who,O
are,O
at,O
risk,O
of,O
COVID,O
‐,O
19,NUMBER
(,O
based,O
on,O
history,O
taking,O
),O
.,O
To,O
defer,O
transplant,O
for,O
1428,DATE
d,O
if,O
screen,O
Some,O
restrictions,O
placed,O
on,O
transplant,O
program,O
.,O
Restrictions,O
may,O
be,O
imposed,O
.,O
to,O
proceed,O
with,O
To,O
proceed,O
with,O
extra,O
caution.d,O
extra,O
caution.d,O
donor,O
program,O
transplant,O
load,O
expected,O
to,O
Medically,O
nonurgent,O
transplants,O
may,O
be,O
put,O
on,O
hold,O
dip,O
.,O
Exceptions,O
may,O
be,O
considered,O
for,O
urgent,O
Precautions,O
under,O
DORSCON,ORGANIZATION
yellow,O
apply,O
.,O
In,O
addiliver,O
transplants,O
tion,O
.,O
diagnostic,O
testing,O
to,O
exclude,O
COVID,O
‐,O
19,NUMBER
is,O
mandated,O
for,O
both,O
donor,O
and,O
recipient,O
Transplant,O
surgeries,O
are,O
likely,O
affected,O
due,O
to,O
diversion,O
of,O
resources,O
to,O
combat,O
COVID,O
‐,O
19,NUMBER
Suspension,O
of,O
nonurgent,O
transplant,O
likely,O
Medi,O
‐,O
cally,O
urgent,O
transplants,O
to,O
be,O
considered,O
on,O
a,O
case,O
by,O
case,O
basis,O
in,O
consult,O
with,O
TxID,O
.,O
This,O
is,O
also,O
dependent,O
on,O
available,O
re,O
‐,O
sources,O
and,O
restrictions,O
imposed,O
based,O
on,O
situation,O
Precautions,O
under,O
DORSCON,ORGANIZATION
orange,O
apply,O
Precautions,O
under,O
DORSCON,O
yellow,O
ap,O
‐,O
ply,O
.,O
In,O
addition,O
.,O
diagnostic,O
testing,O
to,O
exclude,O
COVID,O
‐,O
19,NUMBER
is,O
for,O
both,O
donor,O
and,O
recipient,O
Transplant,O
surgeries,O
are,O
likely,O
affected,O
due,O
to,O
diversion,O
of,O
resources,O
to,O
combat,O
COVID,O
‐,O
19,NUMBER
Suspension,O
of,O
nonurgent,O
transplant,O
likely,O
Medically,MISC
urgent,O
transplants,O
to,O
be,O
considered,O
on,O
a,O
case,O
by,O
case,O
basis,O
in,O
consult,O
with,O
TxID,O
.,O
This,O
is,O
also,O
dependent,O
on,O
available,O
resources,O
and,O
restrictions,O
imposed,O
based,O
on,O
situation,O
Precautions,O
under,O
DORSCON,O
organ,O
apply,O
DORSCON,O
alert,O
was,O
raised,O
to,O
yellow,O
on,O
January,DATE
21,DATE
.,DATE
2020,DATE
.,O
DORSCON,O
alert,O
was,O
raised,O
to,O
orange,O
on,O
February,DATE
7,DATE
.,DATE
2020,DATE
.,O
Donors,O
would,O
have,O
to,O
be,O
screened,O
for,O
respiratory,O
symptoms,O
and,O
travel,O
history,O
to,O
af,O
‐,O
fected,O
areas,O
or,O
CONTACT,O
with,O
COVID,O
‐,O
19,NUMBER
cases,O
or,O
suspects,O
through,O
history,O
taking,O
.,O
Decision,O
to,O
proceed,O
with,O
transplant,O
is,O
based,O
on,O
medical,O
indication,O
.,O
and,O
availability,O
of,O
manpower,O
and,O
resources,O
.,O
Medically,O
urgent,O
cases,O
are,O
given,O
priority,O
.,O
Enhanced,O
infection,CAUSE_OF_DEATH
control,O
precautions,O
are,O
put,O
in,O
place,O
;,O
restrictions,O
are,O
placed,O
on,O
the,O
number,O
of,O
visitors,O
.,O
and,O
healthcare,O
workers,O
attending,O
to,O
the,O
transplant,O
recipient,O
.,O
COVID,O
‐,O
19,NUMBER
.,O
coronavirus,O
disease,CAUSE_OF_DEATH
19,NUMBER
;,O
DORSCON,LOCATION
.,O
Disease,CAUSE_OF_DEATH
Outbreak,MISC
Response,MISC
System,MISC
Condition,MISC
;,O
TxID,O
.,O
Transplant,O
In,O
‐,O
fectious,O
Diseases,CAUSE_OF_DEATH
;,O
WHO,ORGANIZATION
.,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
.,O
MOH,O
issued,O
another,O
advisory,O
on,O
April,DATE
6,DATE
.,DATE
2020,DATE
permitting,O
deceased,O
donor,O
organ,O
transplants,O
.,O
and,O
urgent,O
living,O
donor,O
liver,O
transplant,O
.,O
with,O
the,O
proviso,O
that,O
infection,CAUSE_OF_DEATH
control,O
measures,O
pertaining,O
to,O
the,O
trans,O
‐,O
plant,O
procedure,O
were,O
intact,O
.,O
and,O
that,O
there,O
were,O
available,O
re,O
‐,O
sources,O
(,O
eg,O
.,O
manpower,O
.,O
operating,O
theater,O
facilities,O
.,O
surgical,O
and,O
intensive,O
care,O
beds,O
.,O
blood,O
stock,O
.,O
and,O
adequacy,O
of,O
personal,O
pro,O
‐,O
tective,O
equipment,O
[,O
PPE,O
],O
),O
.16,NUMBER
At,O
the,O
time,DATE
of,O
writing,O
.,O
Singapore,COUNTRY
is,O
experiencing,O
the,O
second,ORDINAL
wave,O
of,O
COVID,O
‐,O
19,NUMBER
infections,CAUSE_OF_DEATH
.,O
which,O
oc,O
‐,O
curred,O
first,ORDINAL
from,O
residents,O
returning,O
from,O
other,O
countries,O
.,O
fol,O
‐,O
lowed,O
by,O
an,O
emergence,O
of,O
new,O
local,O
clusters,O
and,O
cases,O
of,O
unlinked,O
community,O
PRINCIPAL,TITLE
CONSIDERATIONS,O
FOR,O
NEW,O
ORGAN,O
TRANSPLANTATION,O
DURING,O
COVID,O
‐,O
19,NUMBER
First,ORDINAL
and,O
foremost,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
and,O
the,O
disease,CAUSE_OF_DEATH
COVID19,O
are,O
still,O
being,O
defined,O
.,O
What,O
we,O
do,O
not,O
know,O
is,O
the,O
(,O
1,NUMBER
),O
risk,O
of,O
transmission,O
from,O
a,O
positive,O
donor,O
to,O
a,O
recipient,O
.,O
(,O
2,NUMBER
),O
impact,O
of,O
a,O
recipient,O
becoming,O
infected,O
with,O
COVID,O
‐,O
19,NUMBER
and,O
how,O
that,O
influences,O
transplant,O
outcomes,O
.,O
and,O
(,O
3,NUMBER
),O
effective,O
treatment,O
(,O
if,O
any,O
),O
for,O
COVID,O
‐,O
19,NUMBER
.,O
With,O
that,O
in,O
mind,O
.,O
the,O
underlying,O
princi,O
‐,O
ple,O
(,O
to,O
allow,O
safe,O
transplants,O
to,O
continue,O
),O
would,O
be,O
based,O
on,O
any,O
available,O
evidence,O
and,O
adopting,O
best,O
practices,O
to,O
exclude,O
COVID,O
‐,O
19,NUMBER
in,O
the,O
donor,O
and,O
the,O
recipient,O
.,O
while,O
maintaining,O
a,O
smooth,O
operational,O
workflow,O
that,O
also,O
protects,O
healthcare,O
workers,O
(,O
HCWs,O
),O
.,O
MEASURES,O
TO,O
EXCLUDE,O
COVID,O
‐,O
19,NUMBER
IN,O
DONORS,O
AND,O
RECIPIENTS,O
Our,O
COVID,O
‐,O
19specific,O
guidelines,O
for,O
donor,O
and,O
recipient,O
time,O
‐,O
sen,O
‐,O
sitive,O
nature,O
of,O
donation,O
after,O
brain,O
death,O
.,O
The,O
14,NUMBER
‐,O
d,O
lead,O
‐,O
up,O
pe,O
‐,O
riod,O
for,O
living,O
donor,O
transplantation,O
is,O
based,O
on,O
estimates,O
that,O
the,O
median,O
incubation,O
period,O
is,O
approximately,O
5.1,NUMBER
d,O
and,O
that,O
<,O
1,PERCENT
%,PERCENT
will,O
develop,O
symptoms,O
after,O
14,NUMBER
d,O
of,O
active,O
duration,O
.,O
The,O
need,O
for,O
extensive,O
testing,O
has,O
to,O
be,O
balanced,O
against,O
the,O
need,O
to,O
expedite,O
the,O
evaluation,O
process,O
to,O
free,O
up,O
ICU,O
resources,O
and,O
allow,O
a,O
time,O
‐,O
ly,O
donation,O
process,O
that,O
case,O
would,O
automatically,O
be,O
excluded,O
from,O
donation,O
.,O
Donors,O
with,O
any,O
potential,O
risk,O
of,O
exposure,O
to,O
known,O
COVID,O
‐,O
19,NUMBER
Transplantation,O
DIRECT,O
surgical,O
complexity,O
.,O
(,O
b,O
),O
extent,O
of,O
medical,O
comorbidities,O
.,O
and,O
(,O
c,O
),O
immunological,O
risk,O
.,O
bIn,O
general,TITLE
.,O
medically,O
urgent,O
transplants,O
are,O
performed,O
for,O
patients,O
with,O
(,O
a,O
),O
liver,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
with,O
a,O
high,O
28,NUMBER
‐,O
d,O
mortality,O
.,O
(,O
b,O
),O
heart,O
failure,O
patients,O
who,O
are,O
on,O
MCS,O
with,O
evidence,O
of,O
device,O
‐,O
related,O
complications,CAUSE_OF_DEATH
or,O
those,O
who,O
require,O
continuous,O
high,O
‐,O
dose,O
inotropic,O
support,O
.,O
or,O
(,O
c,O
),O
patients,O
with,O
end,O
‐,O
stage,O
lung,O
disease,CAUSE_OF_DEATH
who,O
can,O
not,O
sustain,O
long,O
on,O
the,O
waitlist,O
.,O
patients,O
who,O
are,O
well,O
supported,O
on,O
MCS,O
.,O
and,O
dialysis,O
patients,O
with,O
no,O
access,O
issues,O
.,O
cDecision,O
to,O
proceed,O
with,O
transplantation,O
is,O
contingent,O
on,O
the,O
availability,O
of,O
manpower,O
.,O
operating,O
theater,O
facilities,O
.,O
medical,O
equipment,O
.,O
surgi,O
‐,O
cal,O
and,O
intensive,O
care,O
beds,O
.,O
blood,O
products,O
.,O
and,O
adequacy,O
of,O
PPE,O
.,O
MCS,O
.,O
mechanical,O
circulatory,O
support,O
;,O
PPE,O
.,O
personal,O
protective,O
equipment,O
.,O
transmission,O
routes,O
(,O
or,O
fulfilling,O
the,O
case,O
defini,O
‐,O
tion,O
for,O
a,O
suspect,O
case,O
),O
.,O
such,O
as,O
recent,O
travel,O
history,O
outside,O
of,O
Singapore,COUNTRY
.,O
or,O
possible,O
relationship,O
to,O
any,O
of,O
locally,O
identi,O
‐,O
fied,O
COVID,O
‐,O
19,NUMBER
clusters,O
.,O
are,O
excluded,O
.,O
Donors,O
would,O
also,O
undergo,O
objective,O
testing,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
from,O
a,O
respiratory,O
specimen,O
.,O
Sequential,O
testing,O
also,O
improves,O
the,O
sensitivity,O
of,O
the,O
test,O
.,O
improving,O
the,O
confidence,O
of,O
ruling,O
out,O
COVID,O
‐,O
19,NUMBER
.,O
For,O
deceased,O
donors,O
.,O
an,O
additional,O
computed,O
tomography,O
(,O
CT,STATE_OR_PROVINCE
),O
chest,O
was,O
performed,O
even,O
if,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
that,O
CT,STATE_OR_PROVINCE
imaging,O
find,O
‐,O
ings,O
of,O
viral,O
pneumonia,CAUSE_OF_DEATH
from,O
COVID,O
‐,O
19,NUMBER
predated,O
PCR,O
tests,O
from,O
respiratory,O
samples,O
.,O
allowing,O
for,O
an,O
earlier,O
diagnosis,O
.18,NUMBER
‐,O
20,NUMBER
The,O
criteria,O
for,O
potential,O
transplant,O
recipients,O
are,O
described,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
For,O
patients,O
requiring,O
an,O
urgent,O
transplant,O
.,O
respirato,O
‐,O
ry,O
and,O
febrile,O
illnesses,O
should,O
be,O
extensively,O
evaluated,O
to,O
ex,O
‐,O
clude,O
COVID,O
‐,O
19,NUMBER
.,O
For,O
medically,O
nonurgent,O
transplants,O
.,O
a,O
thorough,O
history,O
is,O
taken,O
from,O
the,O
recipients,O
for,O
the,O
presence,O
of,O
respira,O
‐,O
tory,O
symptoms,O
or,O
fever,CAUSE_OF_DEATH
.,O
as,O
well,O
as,O
contact,O
and,O
travel,O
history,O
.,O
Last,O
.,O
a,O
COVID,O
‐,O
19,NUMBER
test,O
is,O
performed,O
as,O
a,O
final,O
step,O
to,O
exclude,O
asymptomatic,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
before,O
proceeding,O
to,O
surgery,CAUSE_OF_DEATH
.,O
For,O
potential,O
living,O
donor,O
transplant,O
donors,O
and,O
recipients,O
.,O
we,O
rec,O
‐,O
ommended,O
an,O
interim,O
COVID,O
‐,O
19,NUMBER
test,O
at,O
day,DURATION
7,NUMBER
to,O
proactively,O
identi,O
‐,O
fy,O
asymptomatic,O
infection,CAUSE_OF_DEATH
in,O
the,O
candidate,TITLE
that,O
would,O
allow,O
the,O
termination,O
of,O
the,O
14,NUMBER
‐,O
d,O
lead,O
‐,O
up,O
process,O
to,O
transplant,O
.,O
TRANS,O
‐,O
PLANT,O
CENTER,O
POLICIES,O
Informed,O
Consent,O
for,O
Transplant,O
During,O
COVID,O
‐,O
19,NUMBER
Global,O
Outbreak,O
An,O
extra,O
effort,O
was,O
made,O
to,O
counsel,O
the,O
recipients,O
on,O
the,O
risks,O
of,O
proceeding,O
with,O
transplant,O
given,O
the,O
evolving,O
COVID,O
‐,O
19,NUMBER
situation,O
.,O
We,O
described,O
existing,O
steps,O
and,O
pre,O
‐,O
cautions,O
adopted,O
by,O
the,O
institution,O
to,O
exclude,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
both,O
donor,O
and,O
recipient,O
.,O
We,O
emphasized,O
that,O
COVID,O
‐,O
19,DATE
may,DATE
not,O
be,O
fully,O
excluded,O
despite,O
these,O
measures,O
and,O
that,O
the,O
natural,O
history,O
and,O
management,O
of,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
in,O
transplant,O
recipients,O
were,O
not,O
known,O
.,O
Ultimately,O
.,O
these,O
have,O
to,O
be,O
weighed,O
against,O
choosing,O
to,O
stay,O
on,O
the,O
transplant,O
waitlist,O
and,O
the,O
risk,O
of,O
drop,O
‐,O
out,O
.,O
In,O
‐,O
fection,O
Prevention,O
Precautions,O
Hospital,O
‐,O
wide,O
infection,CAUSE_OF_DEATH
prevention,O
precautions,O
were,O
introduced,O
in,O
mid,O
‐,O
January,DATE
2020,DATE
.,O
HCWs,O
were,O
also,O
subject,O
to,O
mandatory,O
twice,O
‐,O
daily,SET
reporting,O
of,O
body,O
temperature,O
and,O
a,O
moratorium,O
on,O
future,DATE
travel,O
to,O
affected,O
countries,O
.,O
HCWs,O
re,O
‐,O
turning,O
from,O
affected,O
areas,O
were,O
placed,O
on,O
a,O
14,NUMBER
‐,O
d,O
stayhome,O
no,O
‐,O
tice,O
.,O
HCWs,O
who,O
were,O
unwell,O
were,O
directed,O
to,O
the,O
staff,O
clinic,O
for,O
prompt,O
evaluation,O
.,O
All,O
HCWs,O
had,O
to,O
(,O
at,O
a,O
minimum,O
),O
wear,O
a,O
surgical,O
mask,O
in,O
all,O
clinical,O
settings,O
.,O
HCWs,O
in,O
the,O
isolation,O
ward,O
manag,O
‐,O
ing,O
patients,O
with,O
or,O
suspected,O
of,O
having,O
COVID,O
‐,O
19,NUMBER
wore,O
full,O
PPE,O
.,O
including,O
N95,O
masks,O
.,O
face,O
shield,O
.,O
long,O
‐,O
sleeved,O
gown,O
.,O
and,O
gloves,O
.,O
Strict,O
guidelines,O
were,O
laid,O
down,O
for,O
surgeons,O
and,O
anesthetists,O
in,O
the,O
operating,O
room,O
with,O
regard,O
to,O
the,O
use,O
of,O
appropriate,O
PPE,O
dur,O
‐,O
ing,O
procedures,O
.,O
Relevant,O
to,O
transplant,O
.,O
full,O
PPE,O
was,O
used,O
for,O
aerosolgenerating,O
procedures,O
such,O
as,O
intubation,O
and,O
extubation,O
or,O
surgery,CAUSE_OF_DEATH
to,O
the,O
respiratory,O
system,O
.,O
The,O
N95,MISC
mask,O
was,O
worn,O
if,O
the,O
Cavitron,O
Ultrasonic,O
Surgical,O
Aspirator,O
was,O
used,O
.,O
The,O
radiology,O
unit,O
screened,O
all,O
requests,O
for,O
investigations,O
.,O
creating,O
a,O
special,O
workflow,O
with,O
segregated,O
areas,O
for,O
patients,O
with,O
worrying,O
clini,O
‐,O
cal,O
and,O
epidemiological,O
features,O
.21,NUMBER
The,O
SingHealth,O
Duke,TITLE
‐,O
NUS,O
Transplant,O
program,O
implemented,O
its,O
own,O
business,O
contingency,O
plans,O
.,O
Those,O
currently,DATE
on,O
or,O
consulting,O
for,O
the,O
inpatient,O
trans,O
‐,O
plant,O
service,O
were,O
not,O
allowed,O
to,O
attend,O
to,O
COVID,O
‐,O
19,NUMBER
cases,O
or,O
suspects,O
.,O
A,O
roster,O
for,O
an,O
active,O
and,O
backup,O
team,O
(,O
s,O
),O
was,O
drawn,O
up,O
where,O
possible,O
.,O
For,O
example,O
.,O
transplant,O
coordinators,O
were,O
divided,O
into,O
2,NUMBER
teams,O
.,O
This,O
allowed,O
the,O
continuation,O
of,O
services,O
if,O
any,O
team,O
member,O
became,O
exposed,O
to,O
.,O
or,O
infected,O
with,O
COVID19,O
.,O
necessi,O
‐,O
tating,O
the,O
need,O
to,O
quarantine,O
the,O
HCWs,O
and,O
team,O
members,O
.,O
As,O
the,O
donor,O
team,O
might,O
need,O
to,O
travel,O
to,O
another,O
hospital,O
for,O
organ,O
procurement,O
.,O
donor,O
and,O
recipient,O
teams,O
were,O
formed,O
without,O
over,O
‐,O
lap,O
to,O
further,O
reduce,O
the,O
risk,O
of,O
Chung,MISC
et,MISC
al,MISC
Donor,MISC
and,O
recipient,O
selection,O
criteria,O
.,O
and,O
additional,O
precautionary,O
measures,O
for,O
transplant,O
Donor,MISC
selection,O
criteria,O
and,O
instructions,O
Living,O
donor,O
transplant,O
program,O
Deceased,MISC
donor,O
transplant,O
program,O
In,O
addition,O
to,O
fulfilling,O
criteria,O
for,O
routine,O
pretransplant,O
workup,O
.,O
ALL,O
of,O
the,O
following,O
apply,O
‐,O
Absence,O
of,O
respiratory,O
symptoms,O
for,O
at,O
least,O
14,NUMBER
d,O
before,O
planned,O
transplant,O
Exclusion,MISC
criteria,O
‐,O
No,O
travel,O
his,O
‐,O
tory,O
outside,O
of,O
Singapore,COUNTRY
for,O
at,O
least,O
14,NUMBER
d,O
before,O
planned,O
‐,O
Res,O
‐,O
piratory,O
specimen,O
(,O
eg,O
.,O
nasopharyngeal,O
or,O
oropharyngeal,O
specimen,O
),O
test,O
negative,O
for,O
SARS,O
‐,O
Co,O
‐,O
V2,O
PCR,O
(,O
2,NUMBER
),O
a,O
before,O
proceeding,O
with,O
transplant,O
‐,O
Donors,O
should,O
not,O
be,O
COVID,O
‐,O
19,NUMBER
suspects,O
The,O
following,O
precautions,O
/,O
advice,O
are,O
recommended,O
:,O
‐,O
Minimize,O
hosting,O
contacts,O
with,O
travel,O
outside,O
of,O
locale,O
(,O
eg,O
.,O
overseas,O
family,O
/,O
‐,O
Avoid,O
con,O
‐,O
gregational,O
/,O
large,O
group,O
meetings,O
(,O
where,O
possible,O
),O
before,O
planned,O
‐,O
When,O
participating,O
in,O
group,O
activities,O
.,O
to,O
wear,O
a,O
mask,O
‐,O
Practice,O
social,O
distancing,O
‐,O
Inform,O
transplant,O
coordinators,O
if,O
respiratory,O
symptoms,O
or,O
febrile,O
illness,CAUSE_OF_DEATH
Recipient,O
selection,O
criteria,O
In,O
addi,O
‐,O
tion,O
to,O
fulfilling,O
criteria,O
for,O
routine,O
pretransplant,O
workup,O
.,O
ALL,O
of,O
the,O
and,O
instructions,O
following,O
apply,O
‐,O
Absence,O
of,O
respiratory,O
symptoms,O
for,O
at,O
least,O
14,NUMBER
d,O
before,O
planned,O
transplant,O
‐,O
No,O
travel,O
history,O
outside,O
of,O
Singapore,COUNTRY
for,O
at,O
least,O
14,NUMBER
d,O
before,O
planned,O
‐,O
Respiratory,O
specimen,O
(,O
eg,O
.,O
nasopharyngeal,O
or,O
oropharyngeal,O
speci,O
‐,O
men,O
),O
test,O
negative,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
PCR,O
(,O
2,NUMBER
),O
a,O
before,O
proceeding,O
with,O
transplant,O
‐,O
Should,O
not,O
be,O
COVID,O
‐,O
19,NUMBER
suspects,O
The,O
following,O
precau,O
‐,O
tions,O
/,O
advice,O
are,O
recommended,O
‐,O
Minimize,O
hosting,O
contacts,O
with,O
travel,O
outside,O
of,O
locale,O
(,O
eg,O
.,O
overseas,O
family,O
/,O
‐,O
Avoid,O
congrega,O
‐,O
tional,O
/,O
large,O
group,O
meetings,O
(,O
where,O
possible,O
),O
before,O
planned,O
‐,O
When,O
participating,O
in,O
group,O
activities,O
.,O
to,O
wear,O
a,O
mask,O
Posttransplant,O
inpatient,O
care,O
for,O
donor,O
Posttransplant,O
inpatient,O
care,O
for,O
recip,O
‐,O
ient,O
Instructions,O
to,O
appointed,O
full,O
time,O
caregiver,O
(,O
s,O
),O
‐,O
Those,O
with,O
ANY,O
travel,O
history,O
outside,O
of,O
Singapore,COUNTRY
in,O
the,O
last,O
28,NUMBER
d,O
;,O
‐,O
COVID,O
‐,O
19,NUMBER
suspects,O
/,O
cases,O
at,O
the,O
time,DATE
of,O
evaluation,O
In,O
addition,O
to,O
fulfilling,O
criteria,O
for,O
routine,O
pretransplant,O
workup,O
.,O
ALL,O
of,O
the,O
following,O
apply,O
(,O
a,O
),O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
PCR,O
(,O
3,NUMBER
specimens,O
),O
b,O
test,O
negative,O
(,O
b,O
),O
CT,STATE_OR_PROVINCE
Chest,O
with,O
no,O
evidence,O
for,O
viral,O
pneumoniac,O
Patients,O
with,O
negative,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
PCR,O
.,O
and,O
CT,STATE_OR_PROVINCE
chest,O
findings,O
not,O
suggestive,O
of,O
viral,O
pneumonia,CAUSE_OF_DEATH
may,O
be,O
considered,O
as,O
potential,O
organ,O
donors,O
on,O
a,O
case,O
by,O
case,O
basis,O
in,O
consult,O
with,O
TxID,O
In,O
addition,O
to,O
fulfilling,O
criteria,O
for,O
routine,O
pretransplant,O
For,O
patients,O
requiring,O
a,O
medi,O
‐,O
cally,O
urgent,O
transplant,O
.,O
ALL,O
of,O
the,O
following,O
apply,O
‐,O
Should,O
not,O
be,O
COVID,O
‐,O
19,NUMBER
suspects,O
‐,O
Should,O
be,O
worked,O
up,O
for,O
any,O
respiratory,O
symptoms,O
/,O
fever,CAUSE_OF_DEATH
.,O
and,O
COVID,O
‐,O
19,NUMBER
ruled,O
out,O
before,O
proceeding,O
with,O
‐,O
In,O
the,O
absences,O
of,O
respiratory,O
symptoms,O
.,O
respiratory,O
specimen,O
(,O
eg,O
.,O
nasopharyngeal,O
or,O
oropharyngeal,O
specimen,O
),O
must,O
still,O
test,O
negative,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
PCR,O
(,O
1,NUMBER
),O
before,O
transplant,O
For,O
medically,O
nonurgent,O
transplant,O
.,O
ALL,O
of,O
the,O
following,O
‐,O
Absence,O
of,O
respirato,O
‐,O
ry,O
symptoms,O
for,O
at,O
least,O
14,NUMBER
d,O
before,O
planned,O
transplant,O
‐,O
No,O
trav,O
‐,O
el,O
history,O
outside,O
of,O
Singapore,COUNTRY
for,O
at,O
least,O
14,NUMBER
d,O
before,O
planned,O
transplant,O
‐,O
Respiratory,O
specimen,O
(,O
eg,O
.,O
nasopharyngeal,O
or,O
oropha,O
‐,O
ryngeal,O
specimen,O
),O
test,O
negative,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
PCR,O
(,O
1,NUMBER
),O
just,O
be,O
‐,O
fore,O
proceeding,O
with,O
transplant,O
‐,O
Should,O
not,O
be,O
COVID,O
‐,O
19,NUMBER
suspects,O
‐,O
Practice,O
social,O
distancing,O
‐,O
Inform,O
transplant,O
coordinators,O
if,O
respiratory,O
symptoms,O
or,O
febrile,O
illness,CAUSE_OF_DEATH
Routine,O
postsurgical,O
care,O
Standard,O
precautionsd,O
Recipient,O
to,O
be,O
nursed,O
strictly,O
in,O
a,O
single,O
room,O
with,O
droplet,O
and,O
standard,O
precautions,O
.,O
Additional,O
contact,O
precautions,O
for,O
those,O
who,O
are,O
colonized,O
with,O
multidrug,O
resistant,O
organisms,O
If,O
febrile,O
illness,CAUSE_OF_DEATH
develops,O
.,O
to,O
work,O
up,O
as,O
appropriatee,O
Have,O
a,O
dedicated,O
full,O
time,O
caregiver,O
During,O
the,O
pretransplant,O
pe,O
‐,O
riod,O
.,O
the,O
potential,O
carer,O
should,O
.,O
in,O
the,O
pretransplant,O
period,O
.,O
adopt,O
lifestyle,O
restrictions,O
that,O
apply,O
to,O
the,O
recipient,O
.,O
It,O
is,O
advisable,O
that,O
during,O
the,O
observation,O
period,O
for,O
the,O
recipient,O
(,O
as,O
described,O
above,O
),O
.,O
the,O
appointed,O
full,O
‐,O
time,O
caregiver,O
(,O
s,O
),O
remain,O
free,O
of,O
respiratory,O
symptoms,O
.,O
If,O
they,O
are,O
unwell,O
at,O
any,O
time,O
be,O
‐,O
fore,O
or,O
after,O
the,O
transplant,O
.,O
they,O
should,O
inform,O
the,O
transplant,O
coordinator,O
.,O
seek,O
medical,O
help,O
/,O
advice,O
.,O
practice,O
social,O
distancing,O
and,O
appoint,O
an,O
alternative,O
caregiver,O
for,O
the,O
potential,O
recipient,O
while,O
they,O
recuperate,O
Transplantation,MISC
DIRECT,MISC
Donor,MISC
and,O
recipient,O
selection,O
criteria,O
.,O
and,O
additional,O
precautionary,O
measures,O
for,O
transplant,O
Living,O
donor,O
transplant,O
program,O
Instructions,O
to,O
house,O
‐,O
hold,O
Deceased,MISC
donor,O
transplant,O
program,O
Advice,O
to,O
caregivers,O
:,O
‐,O
Minimize,O
hosting,O
contacts,O
with,O
travel,O
outside,O
of,O
locale,O
(,O
eg,O
.,O
overseas,O
family,O
/,O
friends,O
),O
‐,O
Avoid,O
congregational,RELIGION
/,O
large,O
group,O
meet,O
‐,O
ings,O
(,O
where,O
possible,O
),O
before,O
planned,O
transplant,O
‐,O
When,O
participat,O
‐,O
ing,O
in,O
group,O
activities,O
.,O
to,O
wear,O
a,O
mask,O
‐,O
Practice,O
social,O
distanc,O
‐,O
ing,O
‐,O
Inform,O
transplant,O
coordinators,O
if,O
respiratory,O
symptoms,O
or,O
febrile,O
illness,CAUSE_OF_DEATH
develops,O
‐,O
Observe,O
good,O
personal,O
hygiene,O
‐,O
Be,O
up,O
to,O
date,O
with,O
their,O
yearly,SET
influenza,CAUSE_OF_DEATH
vaccination,O
Advice,O
to,O
household,O
members,O
‐,O
Observe,O
good,O
personal,O
hygiene,O
‐,O
Be,O
up,O
to,O
date,O
with,O
yearly,SET
influenza,CAUSE_OF_DEATH
vaccination,O
‐,O
For,O
household,O
members,O
who,O
are,O
not,O
the,O
re,O
‐,O
cipients,O
full,O
‐,O
time,O
caregivers,O
:,O
to,O
wear,O
a,O
mask,O
when,O
they,O
partici,O
‐,O
pate,O
in,O
group,O
activities,O
before,O
and,O
posttransplant,O
The,O
first,ORDINAL
specimen,O
should,O
only,O
be,O
obtained,O
after,O
the,O
first,ORDINAL
7,NUMBER
d,O
of,O
the,O
14,NUMBER
‐,O
d,O
observation,O
period,O
for,O
respiratory,O
symptoms,O
;,O
the,O
final,O
specimen,O
should,O
be,O
collected,O
after,O
a,O
14,NUMBER
‐,O
d,O
symptom,O
‐,O
free,O
period,O
.,O
Specimens,O
collected,O
for,O
SARS,O
‐,O
Co,O
‐,O
V2,O
must,O
be,O
collected,O
at,O
least,O
12,NUMBER
h,O
apart,O
and,O
the,O
final,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
PCR,O
must,O
be,O
performed,O
within,O
2448,DATE
h,O
of,O
organ,O
procurement,O
.,O
Patients,O
with,O
viral,O
pneumonia,CAUSE_OF_DEATH
other,O
than,O
COVID,O
19,NUMBER
(,O
eg,O
.,O
rhinovirus,O
.,O
RSV,O
.,O
etc.,O
),O
will,O
be,O
considered,O
for,O
suit,O
‐,O
ability,O
of,O
organ,O
donation,O
on,O
a,O
case,O
‐,O
by,O
‐,O
case,O
basis,O
.,O
During,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
.,O
COVID,O
‐,O
19,NUMBER
has,O
to,O
be,O
considered,O
as,O
a,O
cause,O
for,O
unspecified,O
febrile,O
illness,CAUSE_OF_DEATH
/,O
respiratory,O
tract,O
infection,CAUSE_OF_DEATH
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
PCR,O
and,O
CT,STATE_OR_PROVINCE
Chest,MISC
to,O
be,O
considered,O
as,O
part,O
of,O
workup,O
if,O
ap,O
‐,O
propriate,O
.,O
COVID,O
‐,O
19,NUMBER
.,O
coronavirus,O
disease,CAUSE_OF_DEATH
19,NUMBER
;,O
CT,STATE_OR_PROVINCE
.,O
computed,O
tomog,O
‐,O
raphy,O
;,O
CXR,O
.,O
chest,O
radiograph,O
;,O
PCR,O
.,O
polymerase,O
chain,O
reaction,O
;,O
SARS,O
.,O
Severe,O
Acute,O
Respiratory,O
Distress,O
Syndrome,O
;,O
TxID,O
.,O
trans,O
‐,O
plant,O
infectious,O
reconstruction,O
was,O
performed,O
by,O
the,O
donor,O
team,O
in,O
a,O
separate,O
operating,O
room,O
.,O
before,O
delivery,O
of,O
the,O
organ,O
to,O
the,O
recipient,O
team,O
.,O
These,O
measures,O
taken,O
by,O
the,O
hospital,O
and,O
trans,O
‐,O
plant,O
provision,O
of,O
transplant,O
care,O
.,O
Postoperative,O
Care,O
Recipi,O
‐,O
ents,O
would,O
be,O
nursed,O
strictly,O
in,O
a,O
single,O
room,O
.,O
with,O
droplet,O
and,O
standard,O
precautions,O
.,O
They,O
would,O
be,O
monitored,O
closely,O
for,O
the,O
de,O
‐,O
velopment,O
of,O
infective,O
symptoms,O
and,O
tested,O
for,O
COVID,O
‐,O
19,NUMBER
promptly,O
.,O
if,O
indicated,O
.,O
In,O
the,O
unfortunate,O
event,O
that,O
the,O
recipient,O
becomes,O
positive,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
they,O
will,O
be,O
managed,O
in,O
accordance,O
to,O
the,O
hospital,O
policy,O
.,O
All,O
efforts,O
will,O
be,O
made,O
to,O
establish,O
if,O
this,O
was,O
a,O
donor,O
‐,O
derived,O
infection,CAUSE_OF_DEATH
(,O
DDI,O
),O
.,O
hospital,O
‐,O
acquired,O
.,O
or,O
commu,O
‐,O
nity,O
‐,O
acquired,O
.,O
Hospital,O
and,O
MOH,O
‐,O
sanctioned,O
epidemiology,O
teams,O
would,O
be,O
engaged,O
to,O
perform,O
the,O
necessary,O
contact,O
tracing,O
.,O
Addi,O
‐,O
tional,O
Considerations,O
A,O
key,O
consideration,O
before,O
proceeding,O
with,O
transplant,O
surgery,CAUSE_OF_DEATH
is,O
the,O
availability,O
of,O
operating,O
theater,O
and,O
ICU,O
beds,O
.,O
as,O
these,O
resources,O
may,O
be,O
diverted,O
to,O
the,O
care,O
of,O
pa,O
‐,O
tients,O
with,O
and,O
blood,O
bank,O
stores,O
may,O
compromise,O
the,O
success,O
of,O
transplant,O
surgery,CAUSE_OF_DEATH
in,O
a,O
coagulopathic,O
patient,O
.,O
These,O
factors,O
may,O
influence,O
recipient,O
selection,O
and,O
the,O
decision,O
to,O
proceed,O
with,O
CASE,O
DESCRIPTION,O
In,O
March,DATE
2020,DATE
.,O
when,O
the,O
Disease,CAUSE_OF_DEATH
Outbreak,O
Re,O
‐,O
sponse,O
System,O
Condition,O
(,O
DORSCON,O
),O
alert,O
in,O
Singapore,COUNTRY
was,O
orange,O
at,O
another,O
hospital,O
.,O
The,O
cause,O
of,O
death,O
was,O
a,O
cerebrovascular,O
ac,O
‐,O
cident,O
.,O
Collateral,O
history,O
from,O
the,O
next,O
‐,O
of,O
‐,O
kin,O
established,O
that,O
the,O
potential,O
donor,O
did,O
not,O
have,O
respiratory,O
symptoms,O
before,O
ad,O
‐,O
mission,O
.,O
The,O
donor,O
fulfilled,O
MOHs,O
requirements,O
for,O
deceased,O
donor,O
evaluation,O
.,O
and,O
fulfilled,O
our,O
criteria,O
described,O
were,O
called,O
in,O
to,O
the,O
hospital,O
and,O
evaluated,O
.,O
They,O
too,O
met,O
our,O
inclusion,O
crite,O
‐,O
ria,O
and,O
provided,O
informed,O
consent,O
to,O
proceed,O
.,O
The,O
recipient,O
of,O
both,O
lungs,O
was,O
a,O
middle,O
‐,O
aged,O
patient,O
with,O
postinfective,O
bronchiectasis,O
with,O
pulmonary,O
hypertension,CAUSE_OF_DEATH
on,O
long,O
‐,O
term,O
oxygen,O
therapy,O
but,O
had,O
no,O
other,O
comorbidities,O
or,O
prior,O
chest,O
surgery,CAUSE_OF_DEATH
.,O
Venous,O
‐,O
arterial,O
Extracorporeal,O
Membrane,O
Oxygenation,O
was,O
used,O
for,O
circulatory,O
support,O
and,O
to,O
maintain,O
adequate,O
gas,O
exchange,O
in,O
a,O
patient,O
whose,O
surgery,CAUSE_OF_DEATH
was,O
technically,O
challenging,O
;,O
intraoperative,O
blood,O
transfusion,O
requirements,O
were,O
also,O
reduced,O
with,O
the,O
use,O
of,O
a,O
cell,O
saver,O
device,O
.,O
The,O
liver,O
recipient,O
was,O
a,O
middle,O
‐,O
aged,O
pa,O
‐,O
tient,O
with,O
hepatocellular,O
carcinoma,O
and,O
a,O
low,O
physiologic,O
model,TITLE
for,O
end,O
‐,O
stage,O
liver,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
score,O
.,O
The,O
patient,O
was,O
assessed,O
to,O
be,O
a,O
low,O
surgical,O
risk,O
candidate,TITLE
and,O
was,O
expected,O
to,O
require,O
minimal,O
blood,O
transfusions,O
during,O
surgery,CAUSE_OF_DEATH
.,O
Our,O
usual,O
immunosuppression,O
protocol,O
for,O
lung,O
and,O
liver,O
transplantation,O
does,O
not,O
involve,O
T,O
‐,O
cell,O
depleting,O
induction,O
therapy,O
.,O
Both,O
patients,O
received,O
standard,O
doses,O
of,O
steroid,O
and,O
basiliximab,O
for,O
induction,O
.,O
After,O
transplant,O
.,O
they,O
were,O
maintained,O
on,O
tacrolimus,O
(,O
target,O
trough,O
level,O
between,O
1015,DATE
and,O
810,NUMBER
g,O
/,O
L,O
for,O
the,O
lung,O
and,O
the,O
liver,O
recipients,O
.,O
respec,O
‐,O
tively,O
),O
.,O
mycophenolate,O
mofetil,O
and,O
followed,O
a,O
standard,O
steroid,O
taper,TITLE
.,O
Both,O
recipients,O
are,O
negative,O
for,O
COVID,O
‐,O
19,NUMBER
on,O
postopera,O
‐,O
tive,O
day,DURATION
15,NUMBER
and,O
at,O
the,O
time,DATE
of,O
writing,O
.,O
The,O
recipient,O
of,O
the,O
lung,O
transplant,O
developed,O
bilateral,O
hemothorax,O
.,O
Stenotrophomonas,O
mal,O
‐,O
tophilia,O
ventilator,TITLE
‐,O
associated,O
pneumonia,CAUSE_OF_DEATH
.,O
and,O
required,O
prolonged,O
ventilation,O
due,O
to,O
diaphragmatic,O
paralysis,O
.,O
The,O
recipient,O
of,O
the,O
liver,O
has,O
since,O
been,O
discharged,O
to,O
outpatient,O
care,O
.,O
Closure,O
of,O
a,O
transplant,O
program,O
during,O
an,O
outbreak,O
of,O
because,O
little,O
is,O
known,O
about,O
the,O
pathogen,O
.,O
Invoking,O
the,O
tenet,O
Primum,O
non,O
nocere,O
in,O
this,O
setting,O
means,O
we,O
have,O
to,O
consider,O
the,O
potential,O
for,O
transplant,O
to,O
cause,O
harm,O
by,O
(,O
1,NUMBER
),O
introducing,O
a,O
DDI,O
and,O
(,O
2,NUMBER
),O
placing,O
them,O
at,O
in,O
‐,O
creased,O
risk,O
should,O
they,O
subsequently,O
become,O
infected,O
with,O
COVID,O
‐,O
19,NUMBER
while,O
of,O
coronaviruses,O
to,O
guide,O
evaluation,O
or,O
test,O
‐,O
ing,O
.23.24,NUMBER
Because,O
there,O
is,O
no,O
known,O
treatment,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
there,O
is,O
nothing,O
that,O
can,O
be,O
given,O
empirically,O
or,O
prophylactically,O
to,O
prevent,O
its,O
transmission,O
.,O
Therefore,O
.,O
the,O
only,O
way,O
to,O
prevent,O
COVID19,O
DDI,O
is,O
by,O
excluding,O
infection,CAUSE_OF_DEATH
in,O
the,O
donor,O
.,O
This,DATE
may,DATE
be,O
achieved,O
through,O
history,O
taking,O
and,O
confirmatory,O
testing,O
.25,NUMBER
A,O
de,O
‐,O
tailed,O
history,O
of,O
the,O
donor,O
or,O
from,O
family,O
members,O
or,O
witnesses,O
(,O
in,O
the,O
case,O
of,O
a,O
deceased,O
donor,O
),O
may,O
shed,O
light,O
on,O
the,O
donors,O
exposure,O
to,O
the,O
pathogen,O
.,O
The,O
policy,O
of,O
containment,O
and,O
extensive,O
contact,O
‐,O
tracing,O
in,O
Singapore,COUNTRY
has,O
allowed,O
the,O
chains,O
of,O
transmis,O
‐,O
sion,O
to,O
be,O
identified,O
.,O
In,O
addition,O
.,O
MOH,ORGANIZATION
provides,O
a,O
daily,SET
press,O
release,O
with,O
details,O
on,O
newly,O
diagnosed,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
and,O
sites,O
of,O
potential,O
clusters,O
.5,NUMBER
This,O
dynamic,O
list,O
of,O
COVID,O
‐,O
19,NUMBER
clusters,O
is,O
used,O
at,O
the,O
Emergency,ORGANIZATION
Department,ORGANIZATION
when,O
screening,O
at,O
‐,O
tendees,O
and,O
by,O
organ,O
procurement,O
coordinators,O
.,O
Despite,O
that,O
.,O
there,O
exist,O
several,O
unlinked,O
or,O
yet,O
‐,O
to,O
‐,O
be,O
linked,O
cases,O
.,O
This,O
im,O
‐,O
plies,O
that,O
history,O
taking,O
alone,O
is,O
not,O
foolproof,O
in,O
excluding,O
COVID,O
‐,O
19,NUMBER
and,O
diagnostic,O
tests,O
are,O
required,O
to,O
complete,O
the,O
evalu,O
‐,O
ation,O
.,O
The,O
PCR,O
assay,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
now,DATE
available,O
at,O
many,O
centers,O
.,O
While,O
a,O
negative,O
result,O
may,O
be,O
used,O
to,O
rule,O
out,O
COVID,O
‐,O
19,NUMBER
.,O
we,O
do,O
not,O
know,O
many,O
of,O
the,O
parameters,O
.,O
such,O
as,O
the,O
neg,O
‐,O
ative,O
predictive,O
value,O
of,O
this,O
new,O
test,O
.,O
Even,O
among,O
pathogens,O
such,O
as,O
HIV,CAUSE_OF_DEATH
.,O
Hepatitis,CAUSE_OF_DEATH
B,CAUSE_OF_DEATH
and,O
C,O
that,O
have,O
established,O
tests,O
with,O
a,O
high,O
negative,O
predictive,O
value,O
.,O
window,O
period,O
transmissions,O
have,O
been,O
recorded,O
.26,NUMBER
Furthermore,O
.,O
a,O
recent,O
report,O
of,O
negative,O
tests,O
in,O
a,O
symptomatic,O
patient,O
that,O
on,O
repeat,O
testing,O
became,O
positive,O
is,O
concerning,O
.,O
even,O
though,O
this,DATE
may,DATE
have,O
been,O
related,O
to,O
sampling,O
or,O
testing,O
issues,O
.27,NUMBER
We,O
also,O
considered,O
testing,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
RNAemia,O
in,O
potential,O
donors,O
.,O
RNAemia,O
was,O
documented,O
in,O
15,PERCENT
%,PERCENT
of,O
41,NUMBER
patients,O
in,O
an,O
early,O
series,O
from,O
Wuhan,CITY
.28,NUMBER
RNAemia,O
was,O
seen,O
in,O
both,O
patients,O
that,O
had,O
milder,O
symptoms,O
.,O
and,O
those,O
that,O
required,O
intensive,O
care,O
.,O
Whether,O
RNAemia,O
translates,O
to,O
infection,CAUSE_OF_DEATH
in,O
solid,O
organs,O
such,O
as,O
the,O
liver,O
is,O
unknown,O
.,O
Moreover,O
.,O
the,O
period,O
of,O
RNAemia,O
in,O
relation,O
to,O
onset,O
of,O
the,O
symptom,O
was,O
not,O
described,O
in,O
the,O
report,O
by,O
Huang,PERSON
et,O
al.,O
28,NUMBER
The,O
pervasiveness,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
tissue,O
and,O
body,O
fluids,O
is,O
also,O
not,O
fully,O
defined,O
.,O
A,O
unique,O
fea,O
‐,O
ture,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
its,O
binding,O
to,O
angiotensin,O
‐,O
converting,O
en,O
‐,O
zyme,O
2,NUMBER
receptor,O
and,O
that,O
it,O
might,O
demonstrate,O
tropism,O
to,O
tissues,O
with,O
increased,O
angiotensinconverting,O
enzyme,O
2,NUMBER
expression,O
.,O
al,O
‐,O
though,O
this,O
hypothesis,O
has,O
not,O
been,O
confirmed,O
.29,NUMBER
We,O
know,O
from,O
the,O
report,O
by,O
Chen,PERSON
et,O
al30,O
that,O
among,O
9,NUMBER
pregnant,O
women,O
with,O
COVID,O
‐,O
19,NUMBER
who,O
underwent,O
delivery,O
by,O
cesarean,O
section,O
.,O
there,O
was,O
no,O
vertical,O
transmissionSARS,O
‐,O
CoV,O
‐,O
2,NUMBER
was,O
not,O
identified,O
in,O
the,O
amniotic,O
fluid,O
.,O
cord,O
blood,O
.,O
neonatal,O
throat,O
swab,O
.,O
and,O
breast,O
milk,O
.,O
Presently,O
.,O
the,O
MOH,O
guideline,O
stipulates,O
that,O
a,O
donor,O
must,O
have,O
3,NUMBER
sequential,O
negative,O
throat,O
swab,O
PCR,O
tests,O
for,O
SARSCoV,O
‐,O
2,NUMBER
.,O
These,O
tests,O
should,O
ideally,O
be,O
taken,O
at,O
least,O
12,NUMBER
h,O
apart,O
.,O
and,O
within,O
2448,DATE
h,O
before,O
organ,O
donation,O
.,O
Our,O
institution,O
introduced,O
the,O
need,O
for,O
a,O
CT,STATE_OR_PROVINCE
chest,O
as,O
an,O
added,O
precaution,O
after,O
noting,O
reports,O
that,O
CT,STATE_OR_PROVINCE
chest,O
findings,O
predated,O
a,O
positive,O
PCR,O
result,O
and,O
could,O
be,O
used,O
to,O
identify,O
patients,O
with,O
COVID,O
‐,O
19.18,NUMBER
‐,O
20,NUMBER
In,O
this,O
case,O
.,O
we,O
were,O
suf,O
‐,O
ficiently,O
confident,O
that,O
Chung,PERSON
et,O
al,O
the,O
donor,O
did,O
not,O
have,O
COVID,O
‐,O
19,NUMBER
.,O
given,O
the,O
clinical,O
course,O
in,O
the,O
ICU,O
.,O
the,O
negative,O
PCR,O
tests,O
and,O
a,O
negative,O
CT,STATE_OR_PROVINCE
chest,O
.,O
The,O
COVID,O
‐,O
19,NUMBER
outbreak,O
is,O
evolving,O
and,O
we,O
are,O
currently,DATE
in,O
the,O
acceleration,O
phase,O
of,O
this,O
pandemic,O
.,O
While,O
halting,O
transplantation,O
may,O
appear,O
logical,O
and,O
in,O
the,O
in,O
‐,O
terest,O
of,O
patient,O
safety,O
.,O
it,O
is,O
also,O
not,O
without,O
its,O
harms,O
.,O
Dur,O
‐,O
ing,O
SARS,O
.,O
deferring,O
cancer,CAUSE_OF_DEATH
treatment,O
and,O
postponing,O
diagnostic,O
testing,O
led,O
to,O
what,O
has,O
been,O
called,O
the,O
collateral,O
damage,O
of,O
SARS,O
.4,NUMBER
The,O
same,O
applies,O
to,O
withholding,O
life,O
‐,O
saving,O
transplants,O
for,O
patients,O
on,O
the,O
waiting,O
list,O
who,O
may,O
risk,O
dropping,O
out,O
be,O
‐,O
cause,O
of,O
progression,O
of,O
disease,CAUSE_OF_DEATH
or,O
death,O
.,O
This,O
must,O
be,O
balanced,O
against,O
the,O
challenges,O
posed,O
by,O
COVID,O
‐,O
19,NUMBER
.,O
which,O
is,O
likely,O
to,O
stay,O
for,O
some,O
time,O
.,O
For,O
this,O
very,O
reason,O
.,O
we,O
have,O
proposed,O
a,O
tiered,O
approach,O
to,O
the,O
selection,O
of,O
cases,O
for,O
transplantation,O
.,O
Although,O
we,O
have,O
addressed,O
the,O
issue,O
of,O
donor,O
and,O
recipient,O
selection,O
in,O
the,O
peritransplant,O
period,O
to,O
prevent,O
DDIs,O
.,O
we,O
have,O
to,O
be,O
cog,O
‐,O
nizant,O
that,O
most,O
COVID,O
‐,O
19,NUMBER
infections,CAUSE_OF_DEATH
in,O
the,O
posttransplant,O
period,O
are,O
likely,O
to,O
be,O
acquired,O
from,O
the,O
community,O
.6.13,NUMBER
Nosocomial,O
transmissions,O
may,O
still,O
be,O
possible,O
but,O
at,O
our,O
hospital,O
.,O
strin,O
‐,O
gent,O
infection,CAUSE_OF_DEATH
prevention,O
policies,O
(,O
described,O
above,O
),O
are,O
in,O
place,O
to,O
mitigate,O
this,O
risk,O
.,O
To,O
safely,O
navigate,O
transplantation,O
during,O
this,O
outbreak,O
.,O
we,O
also,O
have,O
to,O
recognize,O
the,O
importance,O
of,O
(,O
1,NUMBER
),O
prevention,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
of,O
face,O
masks,O
.,O
isolation,O
.,O
quarantine,O
.,O
social,O
distancing,O
.,O
and,O
community,O
containment,O
of,O
infected,O
cases,O
),O
in,O
the,O
absence,O
of,O
effective,O
pharmacoprophylaxis13,O
.31,O
and,O
(,O
2,NUMBER
),O
es,O
‐,O
tablishing,O
and,O
continually,O
refining,O
management,O
and,O
treatment,O
strategies,O
for,O
infected,O
transplant,O
recipients,O
based,O
on,O
available,O
evidence,O
.,O
Presently,O
.,O
there,O
is,O
little,O
guidance,O
on,O
the,O
management,O
of,O
the,O
recipient,O
should,O
he,O
or,O
she,O
get,O
infected,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Historical,O
reports,O
of,O
other,O
coronaviruses,O
(,O
SARS,O
and,O
Middle,LOCATION
East,LOCATION
Respiratory,O
Syndrome,O
),O
suggest,O
that,O
they,O
may,O
be,O
lethal,O
in,O
trans,O
‐,O
plant,O
recipients,O
.,O
The,O
liver,O
transplant,O
recipient,O
described,O
by,O
Ku,O
‐,O
mar,DATE
et,O
al3,O
died,O
from,O
SARS,O
.,O
Of,O
the,O
2,NUMBER
renal,O
transplant,O
patients,O
of,O
AlGhamdi,PERSON
et,O
al32,O
who,O
acquired,O
Middle,LOCATION
East,LOCATION
of,O
posttransplant,O
COVID,O
‐,O
19,NUMBER
infections,CAUSE_OF_DEATH
in,O
transplant,O
recipients,O
were,O
community,O
ac,O
‐,O
quired,O
.33,NUMBER
‐,O
40,NUMBER
In,O
addition,O
.,O
outcomes,O
appear,O
more,O
severe,O
.,O
In,O
a,O
case,O
series,O
of,O
20,NUMBER
renal,O
transplant,O
recipients,O
with,O
COVID,O
‐,O
19,NUMBER
by,O
Alberi,PERSON
‐,O
ci,O
et,O
al,O
.40,O
85,PERCENT
%,PERCENT
of,O
cases,O
required,O
supplementary,O
oxygen,O
therapy,O
.,O
20,PERCENT
%,PERCENT
received,O
ICU,O
care,O
.,O
and,O
the,O
mortality,O
rate,O
was,O
25,PERCENT
%,PERCENT
.,O
which,O
is,O
much,O
higher,O
than,O
the,O
case,O
fatality,O
rate,O
of,O
approximately,O
2.3,PERCENT
%,PERCENT
in,O
the,O
general,TITLE
population,O
.8,NUMBER
To,O
improve,O
outcomes,O
of,O
severe,O
COVID,O
‐,O
19,NUMBER
in,O
recipients,O
.,O
it,O
is,O
intuitive,O
then,O
to,O
consider,O
either,O
the,O
use,O
of,O
antiviral,O
therapy,O
or,O
modulation,O
of,O
immunosuppression,O
as,O
observed,O
in,O
these,O
reports,O
.33,NUMBER
‐,O
40,NUMBER
However,O
.,O
there,O
are,O
no,O
proven,O
benefits,O
of,O
either,O
strategy,O
and,O
potential,O
pitfalls,O
exist,O
.,O
With,O
regard,O
to,O
an,O
‐,O
tiviral,O
therapy,O
.,O
there,O
are,O
no,O
established,O
therapies,O
to,O
date,O
.41,NUMBER
Although,O
drugs,CRIMINAL_CHARGE
such,O
as,O
hydroxychloroquine,O
/,O
chloroquine,O
azithromycin,O
.,O
or,O
lopinavir,O
/,O
ritonavir,O
have,O
in,O
vivo,O
activity,O
against,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
and,O
are,O
currently,DATE
being,O
used,O
for,O
patients,O
with,O
severe,O
COVID,O
‐,O
19,NUMBER
.,O
their,O
efficacy,O
is,O
not,O
proven,O
and,O
there,O
may,O
be,O
adverse,O
drug,O
effects,O
.,O
Hydroxychloroquine,O
/,O
chloroquine,O
azithromycin,O
combination,O
is,O
associated,O
with,O
significant,O
gastroin,O
‐,O
testinal,O
disturbances,O
and,O
patients,O
have,O
to,O
be,O
closely,O
monitoring,O
for,O
toxicity,O
(,O
in,O
particular,O
QTc,O
prolongation,O
),O
.,O
Lopinavir,LOCATION
/,O
riton,O
‐,O
avir,O
can,O
also,O
cause,O
diarrhea,O
.,O
It,O
is,O
also,O
a,O
potent,O
inhibitor,O
of,O
CYP,O
3A4,O
.,O
a,O
dose,O
adjustment,O
of,O
the,O
calcineurin,O
inhibitors,O
(,O
tacrolimus,O
/,O
Transplantation,O
DIRECT,O
cyclosporine,O
),O
.,O
is,O
need,O
‐,O
ed,O
.41.42,NUMBER
Preliminary,O
data,O
based,O
on,O
the,O
compassionate,O
use,O
of,O
remdesivir,O
appear,O
promising,O
with,O
68,PERCENT
%,PERCENT
of,O
patients,O
showing,O
clinical,O
improvement,O
.43,NUMBER
This,DATE
may,DATE
be,O
a,O
possible,O
therapeutic,O
option,O
.,O
and,O
we,O
eagerly,O
await,O
the,O
results,O
of,O
ongoing,O
remdesivir,O
clinical,O
tri,O
‐,O
als,O
.40,NUMBER
Where,O
possible,O
.,O
we,O
recommend,O
the,O
enrollment,O
of,O
affected,O
patients,O
into,O
the,O
remdesivir,O
clinical,O
trials,O
.,O
For,O
those,O
who,O
do,O
not,O
qualify,O
.,O
we,O
recommend,O
the,O
use,O
of,O
hydroxychloroquine,O
.,O
In,O
pa,O
‐,O
tients,O
with,O
severe,O
illness,CAUSE_OF_DEATH
.,O
the,O
use,O
of,O
convalescent,O
serum,O
or,O
im,O
‐,O
munomodulatory,O
therapy,O
with,O
tocilizumab,O
may,O
be,O
considered,O
on,O
a,O
case,O
‐,O
by,O
‐,O
case,O
There,O
is,O
no,O
strong,O
evidence,O
on,O
how,O
to,O
modify,O
immuno,O
‐,O
suppression,O
during,O
acute,O
COVID,O
‐,O
19,NUMBER
.,O
The,O
severe,O
illness,CAUSE_OF_DEATH
associated,O
with,O
COVID,O
‐,O
19,NUMBER
is,O
associated,O
with,O
an,O
intense,O
inflammatory,O
re,O
‐,O
sponse,O
.,O
However,O
.,O
there,O
is,O
no,O
proven,O
benefit,O
in,O
the,O
use,O
of,O
corti,O
‐,O
costeroids,O
.,O
and,O
potential,O
deleterious,O
effects,O
(,O
eg,O
.,O
prolonged,O
vi,O
‐,O
ral,O
clearance,O
and,O
risk,O
of,O
secondary,O
bacterial,O
and,O
fungal,O
infec,O
‐,O
tions,O
),O
exists,O
.41.44,NUMBER
On,O
the,O
other,O
hand,O
.,O
it,O
is,O
also,O
not,O
entirely,O
clear,O
how,O
to,O
reduce,O
or,O
discontinue,O
immunosuppression,O
.,O
Although,O
it,O
may,O
bolster,O
native,O
immune,O
responses,O
.,O
it,O
risks,O
graft,O
rejection,O
which,O
will,O
be,O
a,O
devastating,O
complication,O
due,O
to,O
the,O
treatment,O
re,O
‐,O
quired,O
to,O
reverse,O
it,O
.,O
Presently,O
.,O
centers,O
with,O
experience,O
managing,O
COVID,O
‐,O
19,NUMBER
in,O
transplant,O
recipients,O
recommend,O
dose,O
reduction,O
of,O
an,O
‐,O
timetabolites,O
or,O
calcineurin,O
inhibitors,O
in,O
those,O
with,O
severe,O
in,O
‐,O
fections,O
.41.42,NUMBER
In,O
this,O
pandemic,O
.,O
the,O
patient,O
.,O
transplanted,O
or,O
not,O
.,O
is,O
similarly,O
at,O
the,O
risk,O
of,O
succumbing,O
to,O
COVID,O
‐,O
19,NUMBER
either,O
as,O
a,O
patient,O
with,O
end,O
‐,O
stage,O
organ,O
failure,O
or,O
immunosuppressed,O
after,O
transplant,O
.,O
At,O
each,O
phase,O
of,O
the,O
outbreak,O
.,O
the,O
decision,O
to,O
pro,O
‐,O
ceed,O
with,O
transplantation,O
must,O
be,O
guided,O
by,O
the,O
indication,O
for,O
transplant,O
.,O
availability,O
of,O
manpower,O
and,O
resources,O
.,O
and,O
overall,O
safety,O
of,O
all,O
parties,O
involved,O
in,O
the,O
procedure,O
.,O
The,O
known,O
and,O
unknown,O
risks,O
of,O
transplantation,O
are,O
certainly,O
increased,O
amid,O
this,O
COVID,O
‐,O
19,NUMBER
pandemic,O
.,O
However,O
.,O
these,O
risks,O
may,O
be,O
mitigated,O
if,O
the,O
locale,O
practices,O
an,O
effective,O
containment,O
policy,O
.,O
due,O
to,O
diligence,O
made,O
to,O
exclude,O
COVID,O
‐,O
19,NUMBER
in,O
both,O
donor,O
and,O
recipient,O
.,O
and,O
there,O
are,O
robust,O
infectious,O
prevention,O
processes,O
within,O
the,O
hospital,O
.,O
As,O
more,O
data,O
emerge,O
.,O
it,O
is,O
likely,O
that,O
we,O
will,O
gain,O
more,O
knowledge,O
to,O
make,O
the,O
process,O
even,O
safer,O
.,O
Management,O
strate,O
‐,O
gies,O
of,O
COVID,O
‐,O
19,NUMBER
after,O
transplant,O
will,O
continue,O
to,O
evolve,O
as,O
more,O
data,O
emerge,O
.,O
1,NUMBER
.,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
.,O
WHO,O
Director,TITLE
‐,O
Generals,O
opening,O
remarks,O
at,O
the,O
media,O
briefing,O
on,O
COVID,O
‐,O
1911,DATE
March,DATE
2020,DATE
.,O
2,NUMBER
.,O
Grasselli,PERSON
G,PERSON
.,O
Pesenti,PERSON
A,O
.,O
Cecconi,PERSON
M.,O
Critical,O
care,O
utilization,O
for,O
the,O
COVID19,O
outbreak,O
in,O
Lombardy,LOCATION
.,O
Italy,COUNTRY
:,O
early,O
experience,O
and,O
forecast,O
during,O
3,NUMBER
.,O
Kumar,PERSON
D,PERSON
.,O
Tellier,PERSON
R,PERSON
.,O
Draker,PERSON
R,PERSON
.,O
et,O
al,O
.,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
(,O
SARS,O
),O
in,O
a,O
liver,O
transplant,O
recipient,O
and,O
guidelines,O
for,O
donor,O
SARS,O
screening,O
.,O
Am,O
J,O
Transplant,O
.,O
4,NUMBER
.,O
Bernstein,PERSON
M,O
.,O
Hawryluck,O
L.,O
Challenging,O
beliefs,O
and,O
ethical,O
con,O
‐,O
cepts,O
:,O
the,O
sg,O
/,O
covid,O
‐,O
19,NUMBER
.,O
Accessed,O
April,DATE
12,DATE
.,DATE
2020,DATE
.,O
diseases,CAUSE_OF_DEATH
/,O
novel,O
‐,O
coronavirus,O
‐,O
2019,DATE
/,O
situation,O
‐,O
reports,O
.,O
2020,DATE
.,O
Accessed,O
7,NUMBER
.,O
Pan,O
A,O
.,O
Liu,PERSON
L,O
.,O
Wang,PERSON
C,PERSON
.,O
et,O
al,O
.,O
Association,O
of,O
public,O
health,O
interventions,O
with,O
the,O
epidemiology,O
of,O
the,O
COVID,O
‐,O
19,NUMBER
outbreak,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
8,NUMBER
.,O
Lai,O
CC,O
.,O
Shih,PERSON
TP,O
.,O
Ko,O
WC,O
.,O
et,O
al,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
and,O
coronavirus,O
disease,CAUSE_OF_DEATH
‐,O
2019,DATE
(,O
COVID19,O
),O
:,O
the,O
epidemic,O
and,O
the,O
challenges,O
.,O
Int,PERSON
J,PERSON
Antimicrob,PERSON
Agents,O
.,O
9,NUMBER
.,O
Wang,PERSON
C,PERSON
.,O
Horby,LOCATION
PW,LOCATION
.,O
Hayden,PERSON
FG,O
.,O
et,O
al,O
.,O
A,O
novel,O
coron,O
‐,O
avirus,O
outbreak,O
10,NUMBER
.,O
Chen,PERSON
J.,PERSON
Pathogenicity,PERSON
and,O
transmissibility,O
of,O
2019,DATE
‐,O
nCoVA,O
quick,O
overview,O
and,O
comparison,O
with,O
other,O
emerging,O
viruses,O
.,O
Microbes,O
11,NUMBER
.,O
Wei,O
WE,O
.,O
Li,PERSON
Z,PERSON
.,O
Chiew,PERSON
CJ,PERSON
.,O
et,O
al,O
.,O
Presymp,O
‐,O
tomatic,O
transmission,O
of,O
SARSCoV,O
‐,O
2,NUMBER
‐,O
Singapore,COUNTRY
.,O
January,DATE
23,DATE
‐,O
March,DATE
16,NUMBER
.,O
2020,DATE
.,O
MMWR,O
Morb,O
Mortal,O
12,NUMBER
.,O
Rothe,PERSON
C,O
.,O
Schunk,PERSON
M,O
.,O
Sothmann,O
P,O
.,O
et,O
al,O
.,O
Transmission,O
of,O
2019,DATE
‐,O
nCoV,O
infection,CAUSE_OF_DEATH
from,O
an,O
asymptomatic,O
con,O
‐,O
tact,O
in,O
Germany,COUNTRY
.,O
N,O
Engl,PERSON
J,PERSON
Med,PERSON
.,O
13,NUMBER
.,O
Centers,O
for,O
Disease,CAUSE_OF_DEATH
Control,O
and,O
Prevention,O
:,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
gov,O
/,O
coron,O
‐,O
avirus,O
/,O
2019,DATE
‐,O
ncov,O
/,O
cases,O
‐,O
updates/summary.html,O
.,O
Accessed,O
14,NUMBER
.,O
Hol,O
‐,O
loway,O
R,O
.,O
Rasmussen,ORGANIZATION
SA,ORGANIZATION
.,O
Zaza,PERSON
S,PERSON
.,O
et,O
al,O
.,O
Updated,O
preparedness,O
and,O
response,O
framework,O
for,O
influenza,CAUSE_OF_DEATH
pandemics,O
.,O
MMWR,O
Recomm,O
15,NUMBER
.,O
Min,DURATION
‐,O
istry,O
of,O
Health,O
.,O
Singapore,COUNTRY
.,O
Advisory,O
on,O
Health,O
Measures,O
for,O
Organ,O
and,O
Tissue,O
Recovery,O
and,O
Transplantation,O
:,O
COVID,O
‐,O
19,NUMBER
Dorscon,ORGANIZATION
Orange,ORGANIZATION
.,O
Singapore,COUNTRY
:,O
Ministry,ORGANIZATION
of,ORGANIZATION
Health,ORGANIZATION
.,O
Singapore,COUNTRY
;,O
2020,DATE
.,O
16,NUMBER
.,O
Ministry,O
of,O
Health,O
.,O
Singapore,COUNTRY
.,O
Updated,O
advisory,O
on,O
health,O
measures,O
for,O
organ,O
and,O
tissue,O
recovery,O
and,O
transplantation,O
:,O
COVID,O
‐,O
19,NUMBER
Dorscon,O
Organe,O
.,O
Singapore,COUNTRY
:,O
Ministry,ORGANIZATION
of,ORGANIZATION
Health,ORGANIZATION
.,O
Singapore,COUNTRY
;,O
2020,DATE
.,O
17,NUMBER
.,O
Lauer,ORGANIZATION
SA,ORGANIZATION
.,O
Grantz,PERSON
KH,PERSON
.,O
Bi,O
Q,O
.,O
et,O
al,O
.,O
The,O
incubation,O
period,O
of,O
coronavirus,O
dis,O
‐,O
ease,O
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
from,O
publicly,O
reported,O
confirmed,O
cases,O
:,O
es,O
‐,O
timation,O
and,O
application,O
.,O
Ann,O
Intern,TITLE
Med,O
.,O
2020,DATE
.,O
18,NUMBER
.,O
Ai,O
T,O
.,O
Yang,PERSON
Z,O
.,O
Hou,PERSON
H,PERSON
.,O
et,O
al,O
.,O
Correlation,O
of,O
chest,O
CT,STATE_OR_PROVINCE
and,O
RT,O
‐,O
PCR,O
testing,O
in,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
China,COUNTRY
:,O
a,O
report,O
of,O
1014,DATE
19,NUMBER
.,O
Fang,O
Y,O
.,O
Zhang,PERSON
H,PERSON
.,O
Xie,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Sensitivity,O
of,O
chest,O
CT,STATE_OR_PROVINCE
for,O
COVID,O
‐,O
19,NUMBER
:,O
20,NUMBER
.,O
Xie,PERSON
X,PERSON
.,O
Zhong,PERSON
Z,PERSON
.,O
Zhao,PERSON
W,PERSON
.,O
et,O
al,O
.,O
Chest,O
CT,STATE_OR_PROVINCE
for,O
typical,O
2019,DATE
‐,O
nCoV,O
pneumonia,CAUSE_OF_DEATH
:,O
relationship,O
to,O
negative,O
RT,O
‐,O
PCR,O
testing,O
.,O
Ra,O
‐,O
diology,O
.,O
21,NUMBER
.,O
Cheng,PERSON
LT,PERSON
.,O
Chan,ORGANIZATION
LP,ORGANIZATION
.,O
Tan,O
BH,O
.,O
et,O
al,O
.,O
Dj,TITLE
vu,O
or,O
jamais,O
vu,O
?,O
How,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
experience,O
influ,O
‐,O
enced,O
a,O
Singapore,COUNTRY
22,NUMBER
.,O
Angelico,ORGANIZATION
R,ORGANIZATION
.,O
Trapani,PERSON
S,O
.,O
Manzia,O
TM,O
.,O
et,O
al,O
.,O
The,O
COVID,O
‐,O
19,NUMBER
outbreak,O
in,O
Italy,COUNTRY
:,O
initial,O
implications,O
for,O
organ,O
transplantation,O
programs,O
.,O
Am,O
J,O
23,NUMBER
.,O
Chong,ORGANIZATION
PP,ORGANIZATION
.,O
Razonable,PERSON
RR,PERSON
.,O
Diag,O
‐,O
nostic,O
and,O
management,O
strategies,O
for,O
donor,O
‐,O
derived,O
infections,CAUSE_OF_DEATH
.,O
Infect,O
Dis,O
Clin,O
North,O
Am,O
.,O
2013,DATE
;,O
27:253,NUMBER
24,NUMBER
.,O
Len,PERSON
O,PERSON
.,O
Garzoni,PERSON
C,O
.,O
Lum,PERSON
‐,PERSON
breras,O
C,O
.,O
et,O
al,O
.,O
Recommendations,O
for,O
screening,O
of,O
donor,O
and,O
re,O
‐,O
cipient,O
prior,O
to,O
solid,O
organ,O
transplantation,O
and,O
to,O
minimize,O
transmission,O
of,O
donor,O
‐,O
derived,O
infections,CAUSE_OF_DEATH
.,O
Clin,PERSON
Microbiol,PERSON
25,NUMBER
.,O
Seem,O
DL,O
.,O
Lee,PERSON
I,O
.,O
Umscheid,PERSON
CA,STATE_OR_PROVINCE
.,O
et,O
al,O
;,O
United,ORGANIZATION
States,ORGANIZATION
Public,ORGANIZATION
Health,ORGANIZATION
Ser,O
‐,O
vice,O
.,O
PHS,O
guideline,O
for,O
reducing,O
human,O
immunodeficiency,O
virus,O
.,O
hepatitis,CAUSE_OF_DEATH
B,CAUSE_OF_DEATH
virus,O
.,O
and,O
hepatitis,CAUSE_OF_DEATH
C,CAUSE_OF_DEATH
virus,O
transmission,O
through,O
or,O
‐,O
gan,O
transplantation,O
.,O
Public,ORGANIZATION
Health,ORGANIZATION
Rep.,ORGANIZATION
26,NUMBER
.,O
Ison,PERSON
MG,O
.,O
Llata,PERSON
E,PERSON
.,O
Conover,PERSON
CS,O
.,O
et,O
al,O
;,O
HIV,CAUSE_OF_DEATH
‐,O
HCV,O
Transplantation,O
immunodeficiency,O
virus,O
and,O
hepatitis,CAUSE_OF_DEATH
C,CAUSE_OF_DEATH
virus,O
from,O
an,O
organ,O
donor,O
to,O
four,NUMBER
transplant,O
re,O
‐,O
cipients,O
.,O
Am,O
J,O
Transplant,O
.,O
27,NUMBER
.,O
Tay,PERSON
JY,PERSON
.,O
Lim,PERSON
PL,PERSON
.,O
Marimuthu,PERSON
K,PERSON
.,O
et,O
al,O
.,O
De,O
‐,O
isolating,O
COVID19,O
suspect,O
cases,O
:,O
a,O
continuing,O
challenge,O
.,O
Clin,O
Infect,O
Dis,O
.,O
28,NUMBER
.,O
Huang,PERSON
C,PERSON
.,O
Wang,O
Y,O
.,O
Li,PERSON
X,PERSON
.,O
et,O
al,O
.,O
Clinical,O
fea,O
‐,O
tures,O
of,O
patients,O
infected,O
with,O
2019,DATE
novel,O
coronavirus,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
Lancet,O
.,O
29,NUMBER
.,O
Baig,PERSON
AM,O
.,O
Khaleeq,PERSON
A,O
.,O
Ali,PERSON
U,PERSON
.,O
et,O
al,O
.,O
Evidence,O
of,O
the,O
COVID,O
‐,O
19,NUMBER
virus,O
targeting,O
the,O
CNS,O
:,O
tissue,O
distribution,O
.,O
host,TITLE
‐,O
virus,O
interaction,O
.,O
and,O
proposed,O
neurotropic,O
mechanisms,O
.,O
ACS,ORGANIZATION
Chem,ORGANIZATION
Neurosci,O
.,O
30,NUMBER
.,O
Chen,PERSON
H,PERSON
.,O
Guo,PERSON
J,PERSON
.,O
Wang,O
C,O
.,O
et,O
al,O
.,O
Clinical,O
character,O
‐,O
istics,O
and,O
intrauterine,O
vertical,O
transmission,O
potential,O
of,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
in,O
nine,NUMBER
31,NUMBER
.,O
Wilder,PERSON
‐,PERSON
Smith,PERSON
A,O
.,O
Freedman,ORGANIZATION
DO,ORGANIZATION
.,O
Iso,O
‐,O
lation,O
.,O
quarantine,O
.,O
social,O
distancing,O
and,O
community,O
containment,O
:,O
pivotal,O
role,O
for,O
old,O
‐,O
style,O
public,O
health,O
measures,O
in,O
the,O
novel,O
coronavirus,O
(,O
2019,DATE
‐,O
nCoV,O
),O
outbreak,O
.,O
J,O
Travel,O
32,NUMBER
.,O
AlGhamdi,PERSON
M,O
.,O
Mush,PERSON
‐,PERSON
taq,O
F,O
.,O
Awn,PERSON
N,PERSON
.,O
et,O
al,O
.,O
MERS,O
CoV,O
infection,CAUSE_OF_DEATH
in,O
two,NUMBER
renal,O
transplant,O
recipients,O
:,O
case,O
report,O
.,O
Am,O
J,O
Transplant,O
.,O
33,NUMBER
.,O
Zhang,PERSON
H,PERSON
.,O
Chen,PERSON
Y,PERSON
.,O
Yuan,O
Q,O
.,O
et,O
al,O
.,O
Identification,O
of,O
kidney,O
transplant,O
recipients,O
34,NUMBER
.,O
Zhu,PERSON
L,PERSON
.,O
Xu,PERSON
X,PERSON
.,O
Ma,PERSON
K,PERSON
.,O
et,O
al,O
.,O
Successful,O
recovery,O
of,O
COVID,O
‐,O
19,NUMBER
pneumo,O
‐,O
nia,O
in,O
a,O
renal,O
transplant,O
recipient,O
with,O
long,O
‐,O
term,O
immunosuppres,O
‐,O
sion,O
.,O
Am,O
36,NUMBER
.,O
Huang,PERSON
JF,PERSON
.,O
Zheng,PERSON
KI,PERSON
.,O
George,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Fatal,O
outcome,O
in,O
a,O
liver,O
transplant,O
37,NUMBER
.,O
Wang,PERSON
J,PERSON
.,O
Li,PERSON
X,PERSON
.,O
Cao,PERSON
G,PERSON
.,O
et,O
al,O
.,O
COVID,O
‐,O
19,NUMBER
in,O
a,O
kidney,O
transplant,O
patient,O
.,O
Eur,PERSON
Chung,PERSON
et,O
al,O
38,NUMBER
.,O
Seminari,O
E,O
.,O
Colaneri,PERSON
M,O
.,O
Sambo,PERSON
M,O
.,O
et,O
al,O
.,O
SARS,O
Cov2,O
infection,CAUSE_OF_DEATH
in,O
a,O
renal,O
trans,O
‐,O
planted,O
patients,O
.,O
A,O
case,O
report,O
.,O
Am,O
J,O
Transplant,O
.,O
2020,DATE
.,O
40,NUMBER
.,O
Al,O
‐,O
berici,O
F,O
.,O
Delbarba,PERSON
E,PERSON
.,O
Manenti,PERSON
C,O
.,O
et,O
al,O
.,O
A,O
single,O
center,O
observa,O
‐,O
tional,O
study,O
of,O
the,O
clinical,O
characteristics,O
and,O
short,O
‐,O
term,O
out,O
‐,O
come,O
of,O
20,NUMBER
kidney,O
transplant,O
patients,O
admitted,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
pneumonia,CAUSE_OF_DEATH
.,O
Kidney,O
41,NUMBER
.,O
Bhimraj,MISC
A,MISC
.,O
Morgan,ORGANIZATION
RL,ORGANIZATION
.,O
Shumaker,PERSON
AH,O
.,O
et,O
al,O
.,O
Infectious,ORGANIZATION
Diseases,ORGANIZATION
Society,ORGANIZATION
of,ORGANIZATION
America,ORGANIZATION
Guidelines,ORGANIZATION
on,O
the,O
treat,O
‐,O
ment,O
and,O
management,O
idsociety.org/practice‐guide,O
‐,O
line,O
/,O
covid,O
‐,O
19,NUMBER
‐,O
guideline,O
‐,O
treatment,O
‐,O
andmanagement,O
/,O
.,O
Accessed,O
April,DATE
12,NUMBER
.,O
2020,DATE
.,O
42,NUMBER
.,O
Liu,PERSON
H,O
.,O
He,O
X,O
.,O
Wang,O
Y,O
.,O
et,O
al,O
.,O
Management,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
patients,O
43,NUMBER
.,O
Grein,PERSON
J,PERSON
.,O
Ohmagari,PERSON
N,PERSON
.,O
Shin,PERSON
D,PERSON
.,O
et,O
al,O
.,O
Compassionate,O
use,O
of,O
remdesivir,O
for,O
patients,O
with,O
severe,O
COVID,O
‐,O
19,NUMBER
.,O
N,O
Engl,PERSON
J,PERSON
Med,O
.,O
2020,DATE
.,O
44,NUMBER
.,O
Workgroup,O
C,O
‐,O
T.,O
National,O
Center,O
for,O
Infectious,O
Diseases,CAUSE_OF_DEATH
(,O
Singapore,COUNTRY
),O
:,O
interim,O
treatment,O
guidelines,O
for,O
COVID,O
‐,O
19,NUMBER
version,O
1.0,NUMBER
.,O
2020,DATE
.,O
45,NUMBER
.,O
Government,O
of,O
Singapore,COUNTRY
:,O
what,O
do,O
the,O
dif,O
‐,O
ferent,O
DORSCON,O
levels,O
